 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 1 of 75 
 Protocol  
 
Protocol Title:   Dapagliflozin Effect on Symptoms and 
Biomarkers in Patients with Heart Failure  (DEFINE -HF) 
 
Protocol Number:  D1690C00032  
 
ClinicalTrials.gov registration:   [STUDY_ID_REMOVED]  
 
Version Date:    November 4, 2017  
 
 
 
 
 
 
 
 
 
 
 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 2 of 75 
 PROTOCOL SYNOPSIS  
A 12 -week randomized, double -blind, placebo -controlled trial to evaluate  the effects of  once -daily 
dapagliflozin 10 mg on heart failure disease -specific biomarkers  (BNP and NTproBNP) , symptoms, 
health status, and quality of life in patients with chronic heart failure  with reduced systolic function .  
Substudies will also be conducted for explorator y biomarker analys es and effects on arrhythmia  
burden . 
 
Study Hypothesis  
Treatment with dapagliflozin 10 mg daily for 12 weeks will produce greater reductions in NTproBNP 
and improve heart failure symptoms , health status  and quality of life  as compared with placebo in 
patients with chronic heart failure  with reduced systolic function .  
 
Study Centers and Number of Patients Proposed  
This study will be performed at up to 30 centers in the United States. Approximately 250 patients 
will be rando mized over a target enro llment period of approximately 30 months.  
 
 
Primary Objective  
To evaluate the impact of dapagliflozin, as compared with placebo, on heart failure disease -specific 
biomarkers , symptoms, health status, and quality of life in patients with chronic heart failure  with 
reduced systolic function .  
 
Target Population  
Male and female p atients with  chronic heart fail ure with reduced systolic function .   
 
Investigational Product, Dosage, and Mode of Administration  
Dapagliflozin 10 mg  administered orally once daily for 12 weeks, in addition to standard of care for 
chronic heart failure  with reduced systolic function . 
 
 
 
 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 3 of 75 
 Comparator, Dosage and Mode of Administration  
Matching placebo administered orally once daily for 12 weeks, in addition to standard of care for 
chronic heart failure with reduced systolic function . 
 
Study Duration  
After activation of the first site , it is expected that enrollment will take approximate ly 30 months . 
After randomization, dapagliflozin  or placebo will be administered for 12 weeks. Renal function will 
be evaluated 1 week after discontinuation of dapagliflozin or placebo.   
 
Primary Outcome Variable s (two co -primary endpoints will be evaluat ed) 
1. Difference in mean NTproBNP between the treatment and placebo study arms at 6 and 12 
weeks.    
2. Increase of ≥ 5pts in heart failure disease specific quality of life (assessed using the Kansas City 
Cardiomyopathy Questionnaire (KCCQ) summary score) or a ≥  20% decrease in NTproBNP over 
12 weeks.  
Secondary Outcome Variables  
1. Proportion of patients with a ≥ 5pts increase in KCCQ . 
2. Proportion of patients with a ≥ 20% decrease in NTpro BNP . 
3. Proportion of patients with a ≥ 5pts increase in KCCQ and  a ≥ 20% decrease  in NTpro BNP . 
4. Change in KCCQ score over 12 weeks.  
5. Change in 6 minute walk score over 12 weeks.  
6. Change in BNP over 12 weeks.  
7. Change in HbA1c over 12 weeks.  (evaluated separately in patients with and without type 2 
diabetes)  
8. Change in weight over 12 weeks . 
9. Change in systolic blood pressure over 12 weeks . 
Exploratory Outcome Variables  
1. Effects on average weekly loop diuretic dose (furosemide equivalent).  
2. Effec ts on hospitalizations for heart failure.  
3. Effects on rate of urgent outpatient heart failure visits . 
4. Effects on the rate of hospitalizations for heart failure and urgent ou tpatient heart failure 
visits.  
5. Change in NYHA Class over 12 weeks.  
6. Change in NTproBNP and KCCQ at 6 weeks from baseline and 12 weeks from baseline , 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 4 of 75 
 7. Effect on lung fluid volumes  measured by remote dielectric sensing ReDS™ (SensiVest)  over 
the treatment period  (at selected sites) . 
8. Change in mean lung fluid volumes measured by remote dielectric sensing ReDS™ 
(SensiVest) between week 12 and week 13  (at selected sites)   
 
Safety Variables  
1. All cause death  
2. Cardiovascular  death  
3. Non -fatal myocardial infarction (MI)  
4. Stroke  
5. Acute kidney injur y (defined as doubling of serum creatinine based on the modified RIFLE 
criteria)  
6. Adverse events (AEs) and serious adverse events (SAEs) . AEs of special interest will include DKA, 
volume depletion (defined as hypotension, syncope, orthostatic hypotension or  dehydration ) 
and severe hypoglycemic events.  
 
Statistical Methods  
Baseline demographic and clinical data will be described between treatment and placebo study arms as 
mean ± standard deviation for continuous variables and compared using Student’s T -test. Whereas 
discrete variables will be represented as a number and (%) and compared using the χ2 or Fisher’s exact 
test, as applicable.  
The time course of continuous variables will be presented using standard descriptive summary statistics 
calculated at each scheduled measuring time point and the last individual measuring ti me point. 
Moreover, standard descriptive summary statistics will be calculated for the change (absolute or percent) 
from baseline to each scheduled measuring time point after baseline and the last individual measuring 
time point.  
 
Statistical significance will be defined using two -sided tests with α=0.05 , unless otherwise specified . All 
statistical analyses will be performed by the Saint Luke’s Mid America Heart Institute  Department of 
Biostatistics using SAS version 9.4 (SAS Institute, Cary, North Carolina ). 
The first co -primary endpoint of this study is to compare dapagliflozin versus placebo on mean NTproBNP 
at 6 and 12 weeks.  A generalized linear mixed model with a compound symmetry covariance structure 
will be used to estimate  the average effect over 6 a nd 12 weeks controlling for baseline NTproBNP . 
Gamma distribution and log link function will be used because of the skewness nature of NTproBNP. 
Center is included as a random factor to account for cluster ing of patients within centers .  
The second co-primary endpoint, proportion of patients with a  ≥ 5 point KCCQ overall summary score  
increase  or a ≥ 20% decrease in NT proBNP  at either 6 or 12 weeks , will be analyzed using  Mantel -
Haenszel test controlling for center.  
For t he first co -primary endpoint a  sample size of 110 for each group wi ll achieve 80% power with α=0.0 5 
to detect a reduction in NTproBNP  between the two groups of at least 302 pg/mL from baseline to 12 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 5 of 75 
 weeks. The assumptions for this calculation were derived from the BATTLESCARRED  trial where the 
estimated standard deviation for NTproBNP was 1250 pg/mL. We expect the standard deviation in the 
DEFINE -HF Trial to be somewhat lower (961 pg/ml) given lower N TproBNP threshold. Of note, 302pg/mL 
reduction  in NTproBNP  is equivalent to 31.5% of the standard deviation  in NTproBNP  (based on the 
above assumption) .  
The second co-primary endpoint is a combined endpoint of a ≥ 5 point KCCQ overall summary score 
increa se  or a ≥ 20% decrease in NT proBNP. The sample size was determined using two independent 
groups where the anticipated control group percent change is 30%.  A sample size of 110 for each group 
will achieve 80% power with α=0.0 5 to detect a difference in pr oportional cha nge between the two 
groups of 1 8% from baseline to 12 weeks for the second co -primary endpoint.    
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 6 of 75 
 Contents  
PROTOCOL SYNOPSIS  ................................ ................................ ................................ ................................ .... 1 
1 INTRODUCTION  ................................ ................................ ................................ ................................ ... 12 
1.1 Background and Significance  ................................ ................................ ................................ ...... 12 
1.2 Research Hypothesis  ................................ ................................ ................................ ...................  13 
1.3 Rationale for conducting this study  ................................ ................................ ............................  13 
1.4 Benefit/risk and ethical assessment  ................................ ................................ ...........................  13 
1.4.1  Risk Category  ................................ ................................ ................................ .......................  14 
1.4.2  Potential Risks  ................................ ................................ ................................ .....................  14 
1.4.3  Protection Against Risks  ................................ ................................ ................................ ...... 16 
1.4.4  Benefit to Patients  ................................ ................................ ................................ ..............  16 
1.4.5  Informed Consent and Alternatives to Pati ents  ................................ ................................ . 16 
1.4.6  Conclusion  ................................ ................................ ................................ ...........................  16 
2 Study Objective  ................................ ................................ ................................ ................................ ... 17 
2.1 Primary Objective ................................ ................................ ................................ ........................  17 
2.1.1  Secondary Objectives  ................................ ................................ ................................ ..........  17 
2.1.2  Exploratory objective  ................................ ................................ ................................ ..........  17 
2.1.3  Safety objective  ................................ ................................ ................................ ...................  18 
3 Study Plan and Procedures  ................................ ................................ ................................ .................  18 
3.1 Study Design ................................ ................................ ................................ ................................  18 
3.2 Study Procedures  ................................ ................................ ................................ ........................  18 
3.3 Definition of Active Treatment  ................................ ................................ ................................ ... 21 
3.4 Definition of Control Arm  ................................ ................................ ................................ ...........  21 
3.5 Overall Study Duration  ................................ ................................ ................................ ................  21 
4 Study Population  ................................ ................................ ................................ ................................ . 21 
4.1 Inclusion criteria  ................................ ................................ ................................ ..........................  21 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 7 of 75 
 4.2 Exclusion criteria  ................................ ................................ ................................ .........................  22 
5 Study Conduct  ................................ ................................ ................................ ................................ ..... 23 
5.1 Restrictions during the study  ................................ ................................ ................................ ...... 23 
5.2 Patient enrollment and randomization  ................................ ................................ ......................  23 
5.3 Procedures for randomization  ................................ ................................ ................................ .... 23 
5.4 Procedures for handling incorrectly enrolled or randomize d patients  ................................ ...... 24 
5.5 Blinding and procedures for unblinding the study  ................................ ................................ ..... 24 
5.5.1  Methods for ensuring blinding  ................................ ................................ ............................  24 
5.5.2  Methods for unblinding the study  ................................ ................................ ......................  25 
5.6 Treatments  ................................ ................................ ................................ ................................ .. 25 
5.6.1  Identity of study medication  ................................ ................................ ...............................  25 
5.6.2  Doses and treatment regimens ................................ ................................ ...........................  26 
5.6.3  Drug Dispensing Scheme  ................................ ................................ ................................ ..... 26 
5.6.4  Duration of treatment  ................................ ................................ ................................ .........  26 
5.6.5  Labeling  ................................ ................................ ................................ ...............................  26 
5.6.6  Storage  ................................ ................................ ................................ ................................  26 
5.7 Concomitant and post -study treatments  ................................ ................................ ...................  27 
5.7.1  Recording of concomitant medication ................................ ................................ ................  27 
5.8 Treatment Compliance  ................................ ................................ ................................ ...............  27 
5.8.1  Accountability  ................................ ................................ ................................ .....................  27 
5.9 Discontinuations of study medication  ................................ ................................ ........................  27 
5.9.1  General discontinuation criteria  ................................ ................................ .........................  27 
5.9.2  Study -specific di scontinuation criteria ................................ ................................ ................  28 
5.9.3  Procedures for permanent discontinuation of a patient from study medication  ..............  28 
5.9.4  Patient agrees to undergo the Premature Treatment Discontinuation Visit and then 
continue in -person study visits  ................................ ................................ ................................ ...........  28 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 8 of 75 
 5.9.5  Patient refuses to continue in -person study visits but agre es to undergo modified follow -
up……………………………  ................................ ................................ ................................ ..........................  28 
5.9.6  Patient refuses any form of follow -up ................................ ................................ ................  28 
5.9.7  Restart of study medication  ................................ ................................ ................................  28 
5.9.8  Study Closure Visit  ................................ ................................ ................................ ..............  29 
5.10  Withdrawal from study  ................................ ................................ ................................ ...............  29 
5.10.1  Patients permanently discontinuing from study medication  ................................ .............  29 
5.11  Study committees  ................................ ................................ ................................ .......................  29 
5.11.1  Executive Committee  (EC) ................................ ................................ ................................ ... 29 
5.11.2  Steering Committee  ................................ ................................ ................................ ............  30 
5.11.3  Clinical Endpoint Adjudication Committee (CEC) ................................ ................................  30 
5.11.4  Independent Data  and Safety  Monitoring Committee ( IDSMC) ................................ .........  30 
6 Collection of Study Variables  ................................ ................................ ................................ ..............  30 
6.1 Recording of data  ................................ ................................ ................................ ........................  30 
6.2 Data Collection at enrollment and follow -up ................................ ................................ .............  31 
6.2.1  Screening  procedures  ................................ ................................ ................................ ........  31 
6.2.2  Randomization visit (Visit 1)  ................................ ................................ ...............................  32 
6.2.3  Visit 2, 3, 4 and 6 (scheduled telephone contacts)  ................................ .............................  32 
6.2.4  Visit 5 and 7 (on -site visits)  ................................ ................................ ................................ . 32 
6.2.5  Visit 8 (Closeout on -site visit) ................................ ................................ ..............................  33 
6.2.6  Premature Treatme nt Discontinuation Visit (PTDV)  ................................ ...........................  33 
6.3 Patient Monitoring During Study Visits  ................................ ................................ ......................  34 
6.3.1         Patient Monitoring……………………………………………………………………………………… ..…………… .…34  
6.3.2 Physical examination ................................ ................................ ................................ ...........  34 
6.3.3 Phone Visits  ................................ ................................ ................................ .........................  35 
6.4 Vital signs  ................................ ................................ ................................ ................................ .... 35 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 9 of 75 
 6.4.1  Blood pressure  and pulse  ................................ ................................ ................................ .... 35 
6.4.2  Orthostatic  blood  pressure  ................................ ................................ ................................ . 35 
6.4.3  Supine BP and pulse  ................................ ................................ ................................ ............  35 
6.4.4  Standing  BP and pulse  ................................ ................................ ................................ .........  36 
6.5 Six Minute Walk Test  ................................ ................................ ................................ ..................  36 
     6.6        SensiVest Measurement of Lung Fluid Volume ……………………………………………………………………… 36 
6.7 Collection of Kansas City Cardiomyopathy Questionnaire (KCCQ)  ................................ .............  36 
6.8 Laboratory  safety assessment  ................................ ................................ ................................ ..... 37 
7 Biological Sampling Procedu res ................................ ................................ ................................ ..........  37 
7.1 Volume of blood ................................ ................................ ................................ ..........................  37 
7.2 Handling, storage and destruction of biological samples  ................................ ...........................  37 
8 Safety  ................................ ................................ ................................ ................................ ..................  38 
8.1 Definition of adverse events  ................................ ................................ ................................ .......  38 
8.2 Definitions of serious adverse event  ................................ ................................ ..........................  38 
8.2.1  Classification of Death  ................................ ................................ ................................ ........  38 
8.2.2  Universal classification of Myocardial Infarction (MI)  ................................ ........................  39 
8.2.3  Definition of Stroke  ................................ ................................ ................................ .............  39 
8.2.4  Primary ischemic stroke  ................................ ................................ ................................ ...... 39 
8.2.5  Primary hemorrhagic stroke  ................................ ................................ ...............................  39 
8.2.6  Unclassified stroke  ................................ ................................ ................................ ..............  39 
8.2.7  Hospitalizations for heart failure  ................................ ................................ ........................  39 
8.2.8  Urgent outpateint Visits for Heart Failure  ................................ ................................ ..........  39 
8.2.9 Acute Kidney Injury  ................................ ................................ ................................ .............  39 
8.2.10 Ketoacidosis  ................................ ................................ ................................ ........................  39 
8.2.1 1 Volume Depletion  ................................ ................................ ................................ ...............  40 
8.3 Recording of adverse events  ................................ ................................ ................................ .......  40 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 10 of 75 
 8.3.1  Collection of Adverse  Events................................ ................................ ...............................  40 
8.3.2  Follow-up of unreso lved Adverse  Events ................................ ................................ ............  40 
8.3.3  Variables  ................................ ................................ ................................ ..............................  41 
8.3.4  Causali ty collection ................................ ................................ ................................ .............  41 
8.3.5  Adverse Events based on signs and sy mptoms ................................ ................................ ... 41 
8.3.6  Adverse Events based on exa minations  and tes ts ................................ ..............................  42 
8.3.7  Hypoglyce mic events  ................................ ................................ ................................ ...........  42 
8.4 Reporting of serious adverse events ................................ ................................ ...........................  42 
8.4.1  Reporting of serious adverse events to FDA and AstraZeneca  ................................ ...........  43 
9 Ethical and Regulatory Requirements ................................ ................................ ................................ . 43 
9.1 Ethical conduct of the study  ................................ ................................ ................................ .......  43 
9.2 Subject data protection  ................................ ................................ ................................ ..............  43 
9.3 Ethics and regulatory review  ................................ ................................ ................................ ...... 44 
9.4 Informed consent  ................................ ................................ ................................ ........................  44 
9.5 Changes to the protocol and informed consent form  ................................ ................................  44 
9.6 Audits and inspections  ................................ ................................ ................................ ................  45 
9.7 Posting of information on clini caltrials.gov………………………………………………………… .……..……… ….45 
10 Study Management by Saint Luke’s Hospital of Kansas City  ................................ ..............................  45 
10.1  Pre-study activities  ................................ ................................ ................................ ......................  45 
10.2  Training of study site personnel ................................ ................................ ................................ .. 45 
10.3  Monitoring of the st udy ................................ ................................ ................................ ..............  46 
10.4  Source data  ................................ ................................ ................................ ................................ . 46 
10.5  Study agreements  ................................ ................................ ................................ .......................  46 
10.6  Archiving of study documents  ................................ ................................ ................................ .... 46 
10.7  Study timetable and end of study  ................................ ................................ ...............................  46 
11 Data Management by Saint Luke’s Hospital of Kansas City  ................................ ................................  47 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 11 of 75 
 12 Statistical Methods and Sample Size Determination  ................................ ................................ ..........  47 
12.1  Description of analysis sets  ................................ ................................ ................................ .........  47 
12.1.1  Efficacy analysis set  ................................ ................................ ................................ .............  47 
12.1.2  Safety analysis set  ................................ ................................ ................................ ...............  47 
12.2  Methods of statistical analyses  ................................ ................................ ................................ ... 47 
12.2.1  Primary variable  ................................ ................................ ................................ ..................  48 
12.2.2  Secondary variables  ................................ ................................ ................................ ............  48 
12.2.3  Exploratory variables  ................................ ................................ ................................ ..........  49 
12.2.4  Safety variables  ................................ ................................ ................................ ...................  49 
12.2.5  Analysis for safety  ................................ ................................ ................................ ...............  50 
12.3  Determination of sample size  ................................ ................................ ................................ ..... 50 
13 Important Medical Procedures to be Followed by the Investigator  ................................ ...................  50 
13.1  Medical emergencies and Saint Luke’s Hospital  Contacts  ................................ ..........................  50 
13.2  Overdose  ................................ ................................ ................................ ................................ ..... 51 
13.3  Pregnancy  ................................ ................................ ................................ ................................ .... 51 
14 Biomarker Substudy ……………………………………………………………………………………………………………… ….…. 50 
15 Future Research…………………………………………………………………………………………………………………… ……….50 
16 Arrhythmia Substudy………………………………… ………………………………………………………………………… …….…50 
17 SensiVest Lung Fluid Volume Measurements ………………………………………………………………………… ….…52 
18 References  ................................ ................................ ................................ ................................ ..........  52 
19 Appendix A: Heart Failure Hospitalization /Urgent Outpatient Visits  ................................ .................  55 
20 Appendix B: Kansas City Cardiomyopathy Questionnaire (KCCQ) ……………………… ……… ………… ….…….57 
21 Appendix C: Biomarker Substudy…………………………………………………………………………… .………… ……….…61 
22 Appendix D: Arrhythmia Substudy……………………………………………..…………………………… .….……………....66 
23    Appendix E: SensiVest ReDS™ Technology to Estimate Lung Fluid Volumes…………… ……….…………….72 
24    Appendix F: Signature of Principal Inve stigator………………………………………………… …………… ..………..….75 
 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 12 of 75 
 1 INTRODUCTION  
1.1 Background  and Significance  
The prevalence of both heart failure and type 2 diabetes or prediabetes are reaching epidemic 
proportions globally and in the United States.1 In a post hoc analysis of PARAGIDM -HF - a contemporary 
clinical trial of patients with heart failure and reduced ejection fraction (HFrEF), even among patients 
who reported no known history of T2DM, 49% had prediabetes, and 21% had unrecognized T2DM based 
on hemoglobin A1c (HbA1c) criteria.2  In recent clinical trials, HF has emerged as the most common 
cardiovascular (CV) complication of T2DM, exceeding t he incidence of myocardial infraction or stroke.3  
In addition to being common,  incident HF is also arguably the most morbid cardiovascular complication 
of T2DM, with survival of less than 25% over 5 years among older T2D patients.4  
The i ntersection of T2DM, prediabetes and HF is quickly becoming a public health crisis, and 
despite th ese alarming statistics, remarkably little is known on the optimal strategies of managing 
patients with prediabetes, T2DM and HF. To date, no single class of glucose -lowering medications has 
been specifically tested for safety in heart failure patients. Fu rthermore, several existing classes of 
glucose -lowering medications present potential safety issues, specifically in terms of volume overload 
and hospitalizations for heart failure. Foremost among these classes are thiazolidinediones (TZDs)5-7 and, 
possibly, dipeptidyl peptidase (DPP -4), according to results of the SAVOR and EXAMINE clinical trials.8,9  
Other classes of glucose -lowering medications (insulin and sulfonylureas) may lead to weight gain and 
hypoglycemic events10, which potentially impact heart failure symptoms. As a result, evidence -based 
recommendations are currently unavailable for optimal type 2 diabetes or prediabetes mana gement in 
patients with heart failure.  
Sodium glucose cotransporter type 2 inhibitors (SGLT -2i) appear to be the most promising 
therapy to date for patients with HF. While they produce relatively modest HbA1c reduction, SGLT -2i 
exhibit  a novel, entirely in sulin -independent mode of action through increased urinary excretion of 
glucose.11 SGLT -2i may represent a transformational treatment for patients with HF and T2DM, as they 
are the first class of glucose -lowering agents ever to demonstrate a robust benefit for reducing HF 
hospitalizaions.11-13 The EMPA -REG OUTCOME trial randomized 7,020 patients with T2DM and 
established CV disease to 10 or 25 mg of empagliflozin vs. placebo. After a median 3. 1 years, 
significantly fewer patients in the empagliflozin group than in the placebo group experienced the 
primary outcome of MACE (10.5% vs. 12.1%), CV -related death (3.7% vs. 5.9%), or all -cause death (5.7% 
vs. 8.3%).13 There was no difference in outcomes between the10 and 25 mg doses of empagliflozin, with 
both dosage being statistically significantly superior to placebo for primary and secondary endpoints. 13 
Though the trial was predominantly of diabetic patients with coronary artery disease (with only 10% of 
patients having known history of HF at baseline), the maj ority of the benefit appeared to be due to the 
highly significant reduction in hospitalizations for heart failure (a 35% relative risk reduction), and 
prevention of HF -related and arrhythmia -related deaths. The relative risk reduction in HHF was 
statistica lly similar between those with and without a history of HF; however, since overwhelming 
majority of patients did not have HF at baseline, this appeared to represent primarily a HF prevention 
effect.14 
Supporting a class effect for SGLT -2i benefit on hospitali zations for HF, are similar results in the 
Canagliflozin Cardiovascular Assessment Study  (CANVAS Program) . The CANVAS Program was a 
combination of CANVAS, the original canagliflozin cardiovascular safety trial, which was used to gain FDA 
approval in 2013, and a separate CANVAS -R trial, which was combined with CANVAS for the purpose of 
demonstrating cardiovascular benefit. The CANVAS program enrolled a total of 10,142 patients with 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 13 of 75 
 established CVD (65%) or at high risk of CV events (35%), randomized to canag liflozin (100 mg or 300 
mg) or placebo.15 The primary outcome (nonfatal myocardial infarction or stroke, or CV -related death) 
occurred significantly less frequently with canagliflozin than with placebo (26.9 vs. 31.5 per 1000 
patient -years).12 While the reduction in CV and all -cause death with canagliflozin vs. placebo did not 
reach statistically significance , patients in the pooled canagliflozin arm experienced a significant  33% 
relative risk reduction in HHF.12 Real world data from a large multi -national non -interventional study, 
which combined data from well -established registries across 6 countries also supports the notion of a 
class benefit for SGLT -2i and HF outcomes. The CVD -REAL study analyzed over 300,000 T2DM patients 
and compared the HF outcomes in patients being newly initiated on SGLT -2is versus those being started 
on other glucose lowering medications. The main analysis (ma tched 1:1 using propensity score 
methodology), demonstrated a 39% relative risk reduction in HF hospitalizations associated with SGLT -2i 
use vs. other glucose -lowering drugs.16 These reductions were also observed for the outcome of total HF 
events, and were consistent in patients with and without established HF.17  
While the excitement surrounding SGLT -2is as potential therapeutic class for the management o f HF 
is warranted, many questions remain unanswered. It is unclear if the reduction in heart failure 
hospitalizations seen with SGLT -2is to date – which is primarily a signal for HF prevention, will also 
translate to a clinical benefit in patients with est ablished HF, including patients with heart failure and 
reduced ejection fraction (HFrEF). Also given that patients without diabetes (including those with 
prediabetes) would also be expected to have some degree of glucosuria with SGLT -2i treatment, and 
that the CV benefits of SGLT -2i appear to be unrelated to either baseline HbA1c or change in HbA1c, it is 
possible that the potentially beneficial effects of SGLT -2i on reducing HHF may translate to those 
without T2DM.18Additionally more questions regarding t he mechanism of action (MOA) through which  
SGLT -2 inhibit ors may produce a benefit on HF remains unclear, and need further clarification.  To 
provide insight into potential beneficial effects of SGLT -2i in patients with HFrEF (with or without DM), 
as well as to explore potential mechanisms behind these effects,  we plan to perform a  randomized 
clinical trial to evaluate the effects of dapagliflozin, on disease -specific heart failure biomarkers, 
symptoms, health status, and quality of life, in pa tients with chronic heart failure  (both with and without 
DM)  with reduced systolic function.  
1.2 Research Hypothesis  
Treatment with dapagliflozin 10 mg daily for 12 weeks will produce greater reductions in  NTproBNP, 
and improve symptoms , and quality of life  as compared with placebo in patients with chronic heart 
failure  with reduced systolic function . 
1.3 Rationale for conducting this study  
This is a Phase IV study that will determine whether dapagliflozin provides a unique benefit to 
patients with  chronic heart failure with reduced systolic function  by reducing NTproBNP and  
improving patients’ heart failure -related symptoms , health status and quality of life . 
1.4 Benefit/risk and ethical assessment  
Dapagliflozin is approved for  the treatment of type 2 diabetes , therefore patients enrolled in the 
study that have Type 2 diabetes will have an established indication for dapagliflozin therapy. 
Although dapagliflozin is currently not approved in patients without diabetes, when dapagliflozin is 
used either as monother apy or in addition to metformin, it does not cause excess hypoglycemia as 
compared with placebo. No additional safety issues (beyond those observed with dapagliflozin in 
patients with Type 2 diabetes) are anticipated in patients without diabetes treated wi th 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 14 of 75 
 dapagliflozin. Accordingly, we consider the benefit/risk balance to patients enrolled in the study to 
be comparable  to that encountered in the usual clinical practice, with no additional ethical concerns.  
Of note, several large cardiovascular outcome tr ials are currently evaluating various SGLT -2i as 
potential therapies for HFrEF, and include patients with and without diabetes.19-21 
1.4.1 Risk Category   
Considering  dapagliflozin’s mechanism  of action, the previous  clinical  experien ce with dap agliflozin, 
the study’s design featu res (includi ng the inclusion,  exclusion,  and discontinuation  criteria),  and the 
planned  safety procedures,  participation in this  study presents a minimal  and thus  acce ptable  risk to  
the individual  patients  that will be included.  
1.4.2 Potential Risks  
The potential  risks assoc iated  with  dapagliflozin that have  been identified  based  upon the 
mechanism  of action,  the preclinical  results,  and the clinical  experien ce to date,  as well  as 
precau tions included  in the Phase  III program to monitor and/or minimize these  risks, are included  in 
the dapagliflozin prescribing information.  
In clinical Phase  III studies, events  suggestive  of U TI were  reported  in a slightly higher proportion  of 
dapagliflozin-treated patients  than  the placebo  group.  Increased  urinary glucose  excretion  may also 
lead  to an increa sed risk of de veloping  genital  infections.  In Phase  III studies,  the proportions  of 
patients t reated with  dapagliflozin who reported  adverse events that were  indicative of genital 
infection  were higher than those  seen  for placebo.  
In a pooled  analysis of all phase  2b and  3 studies  in the dapagliflozin development  program there  
was an imbalan ce in the frequency of subj ects who had  a serious adverse event of b reast  cancer or 
bladder  cancer. The significance of these  findin gs is not clear at presen t; however  a causal 
relationship  with  the use of dap agliflozin seems  unlike ly. 
Overall there were no imbalances of liver function  test paramet ers in Phase  III studies.  One subject  
on dap agliflozin 5 mg  had a serious adverse event rep orted as dr ug-indu ced acute  hepatitis  and was 
later also diagnosed with  probable autoimmune  hepatitis.  
Due to  the diuretic  effect of dap agliflozin, volume  depletion  (dehydration,  hypovol emia and/or  
hypotension)  is a potenti al concern. In the  clinical program,  from which  subjects  who in  the 
judgment  of inves tigator  may be at risk of dehydration  or volume  depletion  were e xcluded,  very few 
serious events  related  to volume depletion  were reported  and they were equal ly distributed  
between dapagliflozin and placebo groups.  In the  limited  experience  in subjects  with  type 2 diabetes 
on concomitant  loop  diureti cs, events  related to volume  depletion  were more  common  in the 
dapagliflozin groups c ompa red with  the placebo  group. Tempora ry interruption  of dap agliflozin 
should  be considered  for subjects  who de velop volume  depletion.  In the recent analysis of patients 
with preexisting heart failure using pooled data from previous dapagliflozin studies, the rate of 
hypovolemic events was similar between dapagliflozin and placebo.  Of note, all patients in our  study 
will be required to have elevated BNP at baseline, which will further minimize the risk of 
hypovolemic adverse events.  
The U.S. Food and Drug Administration (FDA) recently reported a warning for sodium -glucose 
cotransporter -2 (SGLT2) inhibitors which may lead to ketoacidosis, a serious condition where the 
body produces high levels of blood acids called ketones that may req uire hospitalization. At the time 
of this report there were 20 cases of acidosis reported as diabetic ketoacidosis (DKA), ketoacidosis, 
or ketosis in patients treated with SGLT2 inhibitors. DKA, a subset of ketoacidosis or ketosis in 
diabetic patients, is a type of acidosis that usually develops when insulin levels are too low or during 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 15 of 75 
 prolonged fasting. DKA most commonly occurs in patients with type 1 diabetes and is usually 
accompanied by high blood sugar levels. The FDA reported cases were not typical f or DKA because 
most of the patients had type 2 diabetes and their blood sugar levels, when reported, were only 
slightly increased compared to typical cases of DKA. Factors identified in some reports as having 
potentially triggered the ketoacidosis included  major illness, reduced food and fluid intake, and 
reduced insulin dose. Although the risk of euglycemic DKA is estimated to be very low in this study 
(given the short duration of treatment , and the fact that patients with Type 2 diabetes are at lower 
risk for DKA than Type 1 diabetes, and patients without diabetes are likely not at risk for DKA ) all 
patients will be provided with home urine ketone testing kits, and patients will be monitored for 
symptoms of DKA during in -person visits and study -related pho ne calls. Patients will be instructed to 
self-test for urine ketones and directed to the closest emergency department if the urine ketone 
test is more than mildly positive. The instances of DKA (if any) will be closely monitored as SAE of 
special interest by the study investigators, as well as the Independent Data and Safety Monitoring 
Committee. In addition,  all patients  that have diabetes  in this study will continue  taking  glucose -
lowering medications (other than open -label SGLT -2 inhibitors)  as bac kground  therapy.  These  drugs 
are wide ly used  anti-hyperglycemic treatments  and will  be prescribed according to the approved 
label in patients with known diabetes . 
Dapagliflozin prescribing information states that the drug should not be started in patients with 
eGFR <60.  Per the FDA submission documents the main reason dapagliflozin clinical studies were 
not designed to include patients with eGFR between 30 -45 was b ecause “glycemic efficacy was not 
expected in the absence of adequate renal function.”4 The focus of the DEFINE  Trial is not glycemic 
control, but rather dapagliflozin effects on heart failure endpoints. There are many reasons to 
believe that SGLT2 inhibit ors may have beneficial effects on heart failure and renal endpoints 
regardless of baseline eGFR, including in patients with eGFR between 30 -60. In fact, a recent 
secondary analysis from the EMPA -REG Outcome large scale clinical trial of empagliflozin showed 
dramatic reduction in cardiovascular mortality and hospitalizations for heart failure in patients with 
Type 2 diabetes; patients with eGFR as low as 30 were allowed to be included in that trial.4,5 
Furthermore, in the same trial (EMPA -REG Outcome) marked benefit was observed with 
empagliflozin vs. placebo for clinically important renal endpoints, including doubling of creatinine 
and progression to ESRD.3,6 These effects were observed consistently across the range of baseline 
eGFR. Meta analyses of completed dapagliflozin trials suggest a similar effect of dapagliflozin on 
cardiovascular and renal parameters.7 
The US FDA also issued a more recent safety alert in regards to SGLT2 -inihibtors and potential risk 
for acute kidney injury. The F DA letter mentions 101 cases of acute kidney injury with SGLT -2 
inhibitors, of which only 28 involved dapagliflozin. While the exact denominator is unknown to 
calculate an incidence rate, these 28 open label cases were reported during a time period when ov er 
300,000 prescriptions were filled for dapagliflozin in the US. Further, these spontaneous reports do 
not prove a cause -and effect link between SGLT2 -inhibitors and renal events. The renal safety (and 
in fact nephroprotective effects) of these agents hav e been demonstrated in clinical trials as stated 
above. The safety meta analysis of dapagliflozin trials also showed no evidence for increase in acute 
kidney injury or acute renal failure events.22 
We plan to monitor renal function carefully in the DEFINE -HF study, and doubling of serum  
crea tinine is a safety variable that is being carefully ascertained; fur thermore, all patients in DEFINE -
HF Trial are volume overloaded at baseline given the requirement for significantly elevated 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 16 of 75 
 NTproBNP, and therefore should be at low risk for hypovolemic e vents. The Independent Safety and 
Data Monitoring Committee will also be reviewing safety data continuously.    
Thus, the  benefits  and risks associated  with the background  medication  and comparator t reatment 
are well established and presented  in their respective  appro ved prescribi ng information.  No stu dy 
procedure  will put patients  at a risk significantly b eyond those  ordinari ly encounte red during the 
performa nce of routine  medical  examinations  or routine  tests.  
1.4.3 Protection against Risks  
This study has b een designed with  appropria te measures  in place so as to monitor  and minim ize any 
of the potenti al health risks to participating patients. This i ncludes careful monitoring of patient’s 
vital signs and laboratory values, and the temporary and if necessary permanent discontinuation of 
investigational product in individual patients in whom a potential health risk or a laboratory 
abnormality of clinical concern has been identified.  Further, in order to ensure the s afety of all 
patients participating in this study, an Independent Data and Safety Monitoring Committee ( IDSMC) will 
be formed that will continuously review safety  data , including the incidence of serious adverse events 
(SAEs), and conduct assessments to ensure the ongoing safety of study patients. The IDSMC 
responsibilities, authorities, and procedures are documented in a n IDSMC charter. The personnel 
involved in the clinical study at Saint Luke’s Hospital of Kansas City  will remain blinded to these 
analyses and will have no knowledge of the results presented to the IDSMC.  
1.4.4 Benefit to Patients  
All patients  will cont inue taking  their  active  background   thera py; although  a direct benefit  from  
randomiz ed treatment cannot  be assu red as one half of patients will  receive  placebo,  those with type 
2 diabetes or prediabetes randomized to  dapagliflozin may obtain better glucose control.  In this  study, the 
dose of  dapagliflozin 10 mg  once  daily was chosen to provide  efficacy in improving heart failure 
symptoms and biomarkers, as well as reducing HbA1c  while  mitigating the potential for AEs, based  on 
previous  clinic al experience.  In addition,  among patients randomized to active drug, dapagliflozin is 
expected  to help  maintain better glucose control  among those type 2 diabetes or prediabetes , decr ease 
body weight (or p revent  weight gain)  as well as help  lower  blood  press ure especial ly in patients  with  
elevated  baseline  blood  pressure. All patients  are also expected  to recei ve some  benefit  in the form  
of increased  medical  care/attention when participating in study procedures, which includes at least 5 
clinic visits  with  at least  5 physical  examinations  over  the 13-week stu dy. 
1.4.5 Informed Consent and Alternatives to Patients  
All prospective participants  will be informed of the possible  risks and benefits associated with this  
study, and their consent will be received prior to performing any study-related activity. Wh en a 
prospective participant elects to not particip ate in the study or to withdraw from the stu dy, other 
medications  are available to treat their heart failure , and the patient will not be disadvant aged in any 
way. 
1.4.6 Conclusion  
Considering the pre-clinical and clinical experience with  dapagliflozin and the precautions included  in 
the study protocol, participation in this study presents a minim al and thus acceptable  risk to  patien ts 
who meet  the inclusion /exclusion  criteria and consent  to take  part in the  study. 
For additional  details  on benefits  and risk, pl ease see the dapagliflozin prescribing information . 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 17 of 75 
 2 STUDY OBJECTIVE  
To evaluate the impact of dapagliflozin, as compared with placebo, on heart failure disease -specific 
symptoms, health status , quality of life  and biomarkers  in patient s with chronic heart failure  with 
reduced systolic function .  
2.1 Primary Objective   
1. To compare  the mean NTproBNP between the treatment and placebo study arms at 6 and  12 
weeks.  
2. To compare the proportion of patients that achieve a meaningful change from baseli ne in 
quality of life ( ≥ 5pts  increase in KCCQ overall summary score)  or NT proBNP ( ≥ 20% decrease ) 
over 12 week treatment period between dapagliflozin 10 mg and placebo.  
2.1.1 Secondary  Objectives  
a) To compare the p roportion of patients with a ≥ 5pts increase in the Kansas City Cardiomyopathy 
Questionnaire ( KCCQ ) from baseline over 12 weeks  between dapagliflozin and placebo.  
b) To compare the p roportion of patients with a ≥ 20% decrease in NTpro BNP  from baseline over 
12 week s between dapagliflozin and placebo.  
c) To compare the p roportion of patients with both a ≥ 5pts increase in KCCQ and a ≥ 20% 
decrease in NTproBNP  from baseline over 12  week s between dapagliflozin and placebo.  
d) To compare the change in KCCQ score from bas eline over 12 weeks between dapagliflozin and 
placebo.  
e) To compare the c hange in 6 minute walk  test score from baseline  over 12  week s between 
dapagliflozin and placebo . 
f) To compare the mean  BNP between dapagliflozin and placebo  at 6 and 12 weeks . 
g) To compare the c hange in HbA1c from baseline to week 12 between dapagliflozin and placebo . 
(evaluated separately in patients with and without type 2 diabetes ) 
h) To compare the c hange in weight from baseline over 12  week s between dapagliflozin and 
placebo.  
i) To compare the c hange in systolic blood pressure from baseline over 12  week s between 
dapagliflozin and placebo.  
2.1.2 Exploratory  objective  
1. To compare the e ffects on average weekly loop diuretic dose (furosemide equivalent ) between 
dapagliflozin and placebo.  
2. To compare the e ffects on hospitalizations for heart failure  between dapagliflozin and placebo . 
3. To compare the effects on urgent outpatient heart failure visits between dapagliflozin and 
placebo.  
4. To compare the effects on hospitalizations for heart failure  and urgent outpatient heart failure 
visits  between dapagliflozin and placebo.  
5. To compare the change in NYHA Class from baseline over 12  week s between dapagliflozin and 
placebo.  
6. To compare mean  NTproBNP and change in KCCQ at 6 weeks from baseline and 12 weeks from 
baseline  between dapagliflozin and placebo.  
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 18 of 75 
 7. To compare the e ffect on lung fluid volumes measured by remote dielectric sensing  ReDS™ 
(SensiVest ) between dapagliflozin and placebo  over the course of 12 weeks  (at selected sites) . 
8. To compare the e ffect on lung fluid volumes measured by remote dielectric sensing  ReDS™ 
(SensiVest ) upon discontinuation of dapagliflozin or placebo  (between weeks 12 and 13 ; at 
selected sites ). 
 
2.1.3 Safety  objective s 
To evaluate the safety of dapagliflozin by assessment of AEs including mortality, non -fatal MI, 
stroke, acute kidney injury, volume depletion, severe hypoglycemic events, laboratory values, pulse, 
blood pressure , ketoacidosis  and physical examination findings.   
Patients will be encouraged to keep a diary and perfor m self -monitoring of blood glucose  (for 
patients with established type 2 diabetes only) and weight  (as prescribed by their physician  and 
according to the local standard of care ), as well as specifically self-monitor  for symptoms of 
hypoglycemia and documen t severe  hypoglycemic events, (defined as symptomatic events requiring 
external assistance due to severe impairment in consciousness or behavior with a capillary or 
plasma glucose value <54 mg/dL or blood glucose <54 mg/dL) .).   
Patients will be instructed  to contact study staff if they should  experience any hypoglycemia events 
including severe hypoglycemic events.  
Patient s will be instructed to contact study staff if they should have an unexplained weight loss/gain 
of more than 5 pounds in a day or an unexplained weight loss/gain of more than 10 pounds in a 
week .   
 
3 STUDY PLAN AND PROCEDURES  
3.1 Study Design  
Randomized, double -blind , placebo -controlled trial . The control group will receive placebo  
administered orally once daily for 12 weeks  plus standard  of care. The treatment group will receive 
dapagliflozin  10 mg administered orally once daily  for 12 weeks  plus standard of care . A follow -up 
visit at week 13 will be performed to evaluate  markers of  renal function.  
3.2 Study Procedures  
At the screening visit , participants will undergo a physical exam (including vital signs and weight 
assessment) , a laboratory panel, including HbA1c , BNP, NTproBNP, and a renal panel will be 
performed to determine study eligibility  (Table 1 : Study Plan ). At the randomization visit, 
participants will undergo a physical exam (including vital signs and weight assessment), laboratory 
testing, including HbA1c , BNP, NTproBNP, and a renal panel, complete the KCCQ , perform a 6 
minute walk test  and lung fluid volum e will be measured with the SensiVest  at selected sites .  
Treatment or placebo will be administered for 12 weeks, with follow -up visits at 6 and 12 weeks 
during which a physical exam (including vital signs and weight assessment), labs, KCCQ , a 6-minute 
walk test will be performed,  lung fluid volume will be measured with the SensiVest  (at selected 
sites) , and A Es/SAEs will be recorded . On days 2 and 10, as well as weeks 4 and 9 participants will be 
contacted by phone to evaluate for AEs/SAEs, and encourage c ompliance with the study medication. 
One week after treatment ends, renal function will be evaluated and lung fluid volume will be 
measured with the SensiVest at a follow -up office visit  (at selected sites) . 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 19 of 75 
  
Table 1: Study Plan   
 
  12 –week double -blind 
treatment period   
 
Screening  
Randomization  
  
     
Visit  SJ 1 2 3 4 5 6 7 8 
Weekg) -2 0 2d 10d 4 6 9 12 
PTDV  13 
Office Visit  X X    X  X X 
Phone Visitf)   X X X  X   
Informed consent  X         
Assess eligibility  X X        
Physical Exam a) X X    X  X X 
Vital signs (BP, pulse)  X X    X  X X 
Orthostatic BP, pulse  X X    X  X X 
NYHA Class  X X    X  X X 
Weight X X    X  X X 
Height X         
Body Mass Index  (BMI)m) X X    X  X X 
Waist circumference X X    X  X X 
Medical History  X         
Conco mitant medication  X X X X X X X X X 
Labo ratory ass essments  Xb) X c,k)    X c,k)  X c,k) X d) 
Urine pregnancy  teste) X X    X  X X 
Urine albumin / creatinine 
ratio testi) X X    X  X X 
Dispense Cardiokey  
monitor h) X     X    
6 min ute walk test   X    X  X  
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 20 of 75 
 3.3 SensiVest lung fluid 
measurement at restl)  X    X  X X 
KCCQ   X    X  X  
AEs  X X X X X X X X 
SAEs  X X X X X X X X 
Hospitalizations  
  X X X X X X X X 
ER Visits  
  X X X X X X X X 
Urgent outpatient  
heart failure visits  X X X X X X X X 
Dispense urine ketone strips  X        
Dispense study medication   X        
Return/ redispense study 
medication       X  X  
Study medication accountability       X  X  
 
a) Physical Exam includes : complete  physical  examination  consisting of  general appe arance, head, eyes, ears,  
nose, thr oat, neck,  cardiovascul ar system,  lungs, abdo men, lymph  nodes, extremities, neurological 
system, skin,  musculoskeletal system, height  (screening only) , weight, pulse, blood pressure,  monitoring 
for volume depletion, and assessment for ketoacidosis (difficulty breathing, nausea, vomiting, abdominal 
pain, confusion, and unusual fatigue or sleepiness ). 
b) Screening laboratory assessment includes HbA1c , BNP, NTproBNP  and renal panel.   
c) Randomization, Week 6 and Week 12 l aboratory assessment includes HbA1c , Fasting Glucose, BNP, 
NTproBNP, CBC , renal panel , uric acid, IL-6, HS -CRP, CML, sRAGE, Gal-3, ST-2 and hs-cTnT . 
d) Week 13 l aboratory assessment includes only renal panel.  
e) Only for women  with childbearing potential . 
f) Phone visits include recording any AE or SAE, self -monitoring of weight and blood glucose  (patients with 
established type 2 diabetes only) , and encouraging compliance with study medication . 
g) Visit Windows: There may be up to 2 weeks between the screening and randomiz ation visits.  For patient 
that consent for the arrhythmia monitoring substudy, there must be 2 weeks between the screening and 
randomization visits to allow for the required 2 weeks of wearing the holter monitor.  Week 6, 12 and 13 
clinic visits have a +/ - 2-day visit window.  Phone Visits have a +/ -1-day visit window.   
h) For patient s that consent  for the arrhythmia monitoring substudy , a CARDIOKEY  holter monitor will be 
dispensed at these visits.  After wearing for 2 weeks, the patient will return the CARDIOKEY  holter 
monitor by mail.  
i) The urine specimens collected at 0, 6 and 12 weeks will only be checking urine albumin and urine 
creatinine.  It will not be a standard urinalysis, and any clinical suspicion of urinary tract infection 
will be left to t he local investigator or patient’s primary care physician to order a proper screening 
test to evaluate.    
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 21 of 75 
 j) If a patient is a screen failure at the initial screening visit, they may be rescreened on three  additional 
occasion s at the discretion of the inve stigator.  At the rescreening visit, the patient should be 
treated like a new patient and assigned a new subject number and all screening visit procedures  
should be completed, including obtaining informed consent.  
k) Subjects should be resting in the supin e position for at least 5 minutes prior to collection of blood 
samples for biomarkers at Visit 1 (Week 0 Randomization ), Visit 5 (Week 6 ) and Visit 7 (Week 12 ).  
l) The Sensivest test will only be completed on patients  at selected sites, and  with a BMI of 22 -36 and a 
height of 61  to 77 inches.   Testing may not be completed on all eligible patients.  Testing completion 
will depend upon the availability of the SensiVest testing equipment.  
m) Body mass index (BMI  Formula: weight (kg) / [height (m)]2)) will be calculated using the following 
website17: http://www.cdc.gov/healthyweight/assessing/bmi/adult_bmi/english_bmi_calculator/bmi_calculator.html  
 
3.3 Definition of Active Treatment  
Dapagliflozin 10 mg daily + Standard of Care  for heart failure  with reduced systolic function.  
 
3.4 Definition of Control Arm   
Matching Placebo + Stan dard of Care  for heart failure  with reduced systolic function.  
3.5 Overall Study Duration  
Subjects will participate for a total of 13 weeks. It is estimated that the total study duration will be 
30 months.   
 
4 STUDY POPULATION  
Voluntary participation will be sought from patients  with chronic heart failure  with reduced 
systolic function  at outpatient general cardiology and specialized heart failure clinics . Informed 
consent will be obtained from potentially eligible participants  prior to initiating screening visit 
procedures . 
 
4.1 Inclusion criteria  
1. Age > 18  and < 120 at the screening visit  
2. Established dia gnosis of heart failure (for at least 16 weeks prior to the screening  visit) with 
reduced systolic function (LVEF≤40% due to either ischemic or non -ischemic etiology) 
documented by an imaging modality (echocardiography, nuclear imaging, LV angiography, 
mag netic resonance imaging) within the past 24 months. Any local measurement of LVEF by 
any modality within the eligibility range made within the past 24 months is acceptable 
provided there has been no subsequent LVEF measurement above 40%.  
3. No change in diuretic management for 1 week  prior to screening visit  or between the 
screening and randomization visit  
4. NYHA class II or III heart failure symptoms at the screening and randomization visit  
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 22 of 75 
 5. BNP ≥100 pg/mL  and/or NT proBNP ≥ 400 pg/mLa)Ŧ at the screening visit  
6. Ability to provide informed consent  prior to initiating screening visit procedures  
4.2 Exclusion  criteria  
1. Decompensated heart failure (hospitalization for heart failure within the 30 days prior to 
screening or NYHA class IV heart failure symptoms at screening)  
2. History of t ype 1 diabetes  
3. Estimated glomerular filtration rate (eGFR) < 30 at the screening visit  by modified MDRD 
equation  GFR (mL/min/1.73 m2 ) = 175 x (Scr) -1.154 x (Age)-0.203 x (0.742 if female) x (1.210 if 
African American)18  
4. Admission for an acute coronary syndrome  (ST-elevation MI, non -ST-elevation MI, or 
unstable angina) , percutaneous coronary intervention, or cardiac surgery within 30 days 
prior to the screening visit .  
5. Admission for cardiac resynchronization therapy (CRT ) within 90 days prior to the screening 
visit 
6. Planned cardiovascular revascularization  (percutaneous intervention or surgical)  or major 
cardiac surgery  (coronary artery bypass grafting, valve replacement, ventricular assist 
device, cardiac transplantation,  or any other surgery requiring thoracotomy)  or CRT within 
the 90 days  after the screening visit.  
7. Participation in any  interventional  clinical trial  (with an investigational drug or device) that is 
not an observational registry  within the 8 weeks  prior to the screening visit . 
8. History of hypersensitivity to dapagliflozin  
9. For women of child -bearing potential: Current or planned pregnancy or currently lactating .   
Women who are surgically sterile or those who are postmenopausal for at least 1 year ar e 
not considered to be of child -bearing potential. Women of child -bearing potential, who are 
sexually active, must agree to use a medically -accepted method of birth control for the 
duration of the study.  Acceptable birth control methods include: (1) surgi cal sterilization 
(such as a hysterectomy or bilateral tubal ligation), (2) progesterone hormonal 
contraceptives (birth control pills or implants), (3) barrier methods (such as a condom or 
diaphragm) used with a spermicide, or (4) an intrauterine device (I UD).  Women of child -
bearing potential will have a urine pregnancy test at every clinic visit and it must be negative 
to continue study participation.   
 
10. Life expectancy <1 year  at the screening visit  
11. Patients who are volume depleted based upon physical exa mination  at the time of the 
screening or randomization visit  
12. BNP < 100 pg/mL  and NT proBNP< 400 pg/mL  at the screening visit  £ 
13. Patients currently being treated with any SGLT -2 inhibitor  (dapagliflozin, canagliflozin, 
empagliflozin)  or having received treatment with any SGLT -2 inhibitor within the 12 weeks 
prior to the screening visit.  
14. Avera ge supine systolic BP <90 mmHg  at the screening or randomization visit  
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 23 of 75 
 15. Past or current history of bladder cancer   
16. Active Hematuria  
17. Donation of blood or bone marrow 12 weeks prior  to the screening visit  and no planned 
donation s during the study period  
18. Heart failure  due to restrictive cardiomyopathy, active myocarditis, constrictive pericarditis, 
severe s tenotic valve disease, and HOCM (hypertrophic obstructive cardiomyopathy).  
 Ŧ  For patients with permanent atrial fibrillation  inclusion thresholds will be BNP ≥ 125 pg/mL or 
NTproBNP ≥ 600 pg/mL  
£For patients with permanent atrial fibrillation  exclusion thresholds will be BNP< 125 pg/mL and 
NTproBNP< 600 pg/mL  
5 STUDY CONDUCT  
5.1 Restrictions during the study  
Patients should be fasting from all food and beverages  (except water)  at least 6 hours before blood 
samples are taken for laboratory analysis  at a clinic visit  with the exception of the screening visit.  It 
is preferred but not required that patients be fasting at the screening visit . Patients should not use 
alcohol for 24 hrs or use tobacco for 12 hrs prior to testing  at a clinic visit . Patients with established 
type 2 diabetes  or prediabetes  should not take  any glucose -lowering medi cation when they are fasting.  
On the  day of a clinic visit, inv estigational product and other concomit ant medi cations  will be taken 
in the morning, after completion  of cer tain required  study proced ures.  For patients with established 
type 2 diabetes on basal insulin, it is recommended they only take ½ of their basal dose the evening 
before they are planning to fast for an office visit.  Patients  shall not be allowed to use any 
prescribed SGLT -2 inhibitors (dapagliflozin, canagliflozin, empagliflozin),  other than the 
investigational product, at any time during the study. Patients shall not be allowed to  donate blood 
or bone marrow at any time during the study.   Patients shall not be allowed to participate in any 
other interventional clinical trial (with  a drug or device) for the duration of the study.  
5.2 Patient enrollment and randomization  
The Principal Investigator or delegate will: 
1. Obtain signed informed consent from the potential patient before any study specific 
procedures are performed  
2. Determine pa tient eligibility  
3. Assign potential patients a sequential  enrollment number  in the form of Site ID and 
enrollment number i .e.: XXX-XXX 
4. Assign enrolled patient a unique randomization code using Sharp Clinical Services 
interactive web response technology system . 
 
If a patient withdraws from participation in the study, then their enrol lment  number cannot be reused. 
Patients can only be randomized into the study once.  
 
5.3 Procedures for randomization  
Sharp Clinical Services will provide a state -of-the-art interactive web response technology s ystem 
(IRT). Sharp ’s IRT is an innovative value -based product for Subject enrollment, randomization, 
capturing clinical data, drug shipments, and managing drug supply.  
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 24 of 75 
 Sharp ’s IRT  is 21 CFR Part 11 compliant, user -friendly, and provide value to all users with big 
reductions in study start up times. The IRT System ensures data integrity, accelerates clinical site 
initiations, and can provide real -time metrics for subjects, sites and st udy inventory for approved 
users.  
Solutions and Services include:  
• 24/7 Operation  
• Site Administration and Tracking  
• Study Drug Distribution and Resupply Management  
Training and User -Materials:  
During system development, Sharp creates a study -specific user manual and Quick Reference Guide 
for the IRT System. Site and client users are trained at investigator meetings or scheduled web -
based training sessions .  
 
5.4 Procedures for handling incorrectly e nrolled or randomized  patients  
Patients who fail to meet the inclusion/exclusion criteria  should not, under any circumstances, be 
enrolled or randomized . There can be no exceptions to this rule.  
The following steps should be taken in the event that a patie nt, who does not meet 
inclusion/exclusion criteria, is found to have been inadvertently randomized  in the study:  
1. The investigator should inform the Saint Luke’s Hospital of Kansas City  study team 
physician immediately. Ensuring patient safety must always b e the number one priority . 
2. Study treatment must be discontinued in all cases where continued treatment is 
deemed to pose a safety risk to the patient. After a discussion between the study team 
physician and investigator, a decision may be reached that the patient should 
discontinue study medication. The rationale for discontinuing study medication  must be 
clearly documented. The patient should remain in the study for follow up in accordance 
with defined study procedures including follow -up on endpoints  thro ugh the end of t he 
study consistent with the FAS  principle . 
3. In those cases where continuation of study therapy is judged not to present a concern 
related to safety and disease management, the rationale for continuing  study therapy 
must be clearly documente d. The patient should continue follow up in  accordance with 
defined study procedures.  
 
5.5 Blinding and procedures for unblinding the study  
5.5.1 Methods for ensuring blinding  
The treatment allocation in this study will be double blind. Dapagliflozin (1 0 mg) tablets  and 
matching dapagliflozin  placebo tablets will be provided , identical in appearance and with the same 
number , size, and packaging of tablets. Each bottle  will be labe led with a unique bottle  ID number 
that will be used to assign the treatment to the pati ent but will not indicate treatment allocation to 
the investigator.  
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 25 of 75 
 No member of the extended study team at Saint Luke’s Hospital of Kansas City , the E C, the CEC, or 
personnel at investigational centers  will have access to the randomization  scheme during the 
conduct of the study, with the exception  of the Sharp Clinical Services , and the Biostatistics  
department at  Saint Luke’s Hospital of Kansas City . 
The IDSMC will have access to the individual treatment codes and will be able to merge the se with 
the collected study data while the study is o ngoing . The IDSMC will review safety data on a periodic 
basis, including the incidence of SAEs, and conduct safety assessments to ensure the ongoing safety 
of study patients. The IDSMC responsibilities, authorities, and procedures will be documented in a 
IDSMC charter. The personnel involved in the clinical study at Saint Luke’s Hospital of Kansas City  
will remain blinded to these analyses and will have no knowledge of the results presented to the 
IDSMC. 
 
5.5.2 Methods for unblinding the study  
Individual treatment codes, indicating the treatment allocation for each randomized  patient, will be 
available to the investigator(s) or pharmacists from the  Sharp Clinical IVR/IWR system . Routines for 
this w ill be describ ed in the Sharp Clinical IVR/IWR system user manual that will be provided to each 
study site . 
The treatment code should not be broken except in medical emergencies when the appropriate 
management of the patient requires knowledge of the treatment. The Saint Luke’s Hospital of 
Kansas City  physician  (Mikhail Kosiborod  or delegate ) should be consulted whenever possible prior 
to the investigator breaking the blind. The investigator documents and reports the action to Saint 
Luke’s Hospital of Kansas City , without revealing the treatment given to the patient to the Saint 
Luke’s Hospita l of Kansas City  staff. The number of individuals at the study site who become aware 
of the treatment status should be kept to an absolute minimum including keeping the patient 
blinded if possible. Treatment with study medication should be continued if con sidered appropriate.  
Saint Luke’s Hospital of Kansas City  retains the right to break the code for SAEs that are unexpected 
and are suspected to be causally related to a study drug and that potentially require expedited 
reporting to regulatory authorities. Treatment codes will not be broken for the planned analyses of 
data until all decisions on the evaluability of the data from each individual patient have been made 
and documented.  
 
5.6 Treatments  
5.6.1 Identity of study medication  
 
Table 2  Identity of study medicati on 
Study Medication  Dosage form and strength  Manufacturer  
Dapagliflozin  Bicon vex, diamond shape,  green 
tablet 10 mg (Size: 11 mm) 
 AstraZeneca  
Matching placebo  for 
dapaglif lozin 10 mg  Bicon vex, diamond shape,  green 
tablet (Size: 11 mm) AstraZeneca  
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 26 of 75 
  
5.6.2 Doses and treatment regimens  
At the randomization visit eligible patients will be randomly assigned to 1 of 2 treatments:  
• Dapagliflozin 1 0 mg, administered orally once daily for the 12 weeks.  
• Matching placebo for d apagliflozin 1 0 mg, administere d orally once daily for the 12 weeks.  
The investigational product dapagliflozin  and matching  placebo will be taken orally. The 
investi gational  prod uct should  be taken  once daily in the morni ng and at appro ximate ly the same  
time  of the  day during the study period.  Nevertheless  prior  to each office visit, patients with 
established type 2 diabetes  or prediabetes  should  be instructed  not to take  any glucose -lower ing 
medi cation in the  morning  and to abstain from all food and bever ages for 6  hours; however,  drinking  
water is allowed.  On the day of an office visit, investigational product and other concomit ant 
medi cations  will be taken in the morning, after completion  of cer tain required  study proced ures. 
5.6.3 Drug Dispensing Scheme  
At randomization , one  (1) bottle of dapagliflozin 10 mg or matching placebo will be dispensed , with the 
bottle  containing 105 tablets.  
5.6.4 Duration of treatment  
The control group will receive placebo  administered orally once daily for 12 weeks  plus standard of care. 
The treatment group will receive dapagliflozin 10 mg administered orally once daily for 12 weeks  plus 
standard of care . Subjects will participate for a total of 13 weeks.  
5.6.5 Labeling  
Labels will be prepared in accordance with Good Manufacturing Practice (GMP) and local regulatory 
guidelines. The labels will fulfill GMP Annex 13 requirements for labeling.  The label will include at least 
the following information:  
• Name of sponsor : Saint Luke’s Hospital of Kansas City  
• Study drug(s) dosage form, route of administration, and quantity of dosage units  
• Study code  
• Enrol lment code (will be added by the investigator when investigational product is dispensed)  
• Kit ID  
• Directions for use (For oral use)  
• Storage conditions  
• “for clinical trial use only”  
• “keep out of reach of children”  
5.6.6 Storage  
All study drugs should be kept in a secure place under appropriate storage conditions and in the 
original container. The study medication label and dapagliflozin pres cribing information  specify 
appropriate storage.  
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 27 of 75 
 5.7 Concomitant and post -study treatments  
5.7.1 Recording of concomitant medication  
Detailed recording of all concomitant medications will be made at screening, randomization , and all 
subsequent visits. It  will includ e all medication changes , but  glucose lowering  and heart failure 
medications  in particular .  
5.8 Treatment Compliance  
The administration of study medication should be recorded .  All stops of study medication 
prescribed by the investigator should be recorded. I n addition, any non -prescribed temporary stops 
(>1 week) of study medication should be recorded.  
Missed doses of dapagliflozin  or placebo blinded study medication should not be taken.  I f a dose is 
missed , the next regularly scheduled dose should be taken and should not be doubled.  
 
5.8.1 Accountability  
The study medication provided for this study will be used only as directed in the study protocol.  The 
study personnel will account for all study medication dispensed to and returned from the patient.  
Patients will  be asked to bring all unused study medication and empty packages to the  site at each 
office visit. The investigator or delegate will record  the number  of returned tablets and make an 
assessment regarding patient treatment compliance. Any patient found to be noncompliant would 
be counseled on the importance of taking their study medication as prescribed.  
Any study medication deliberately or accidentally destroyed must be recorded. Any discrepancy 
between dispensed and returned study medication should be explained.  
The investigator will retain the returned medication until the termination of the Clinical Study. Then 
the investigator will retur n any unused medication to  Sharp Clinical Services  for destruction of all 
unused study medication.  Saint Luke’s Hospital of Kansas City  is responsible for confirming the 
investigator or delegate has recorded the quantities of returned and unused tablets at  a patient 
level before medication is returned to Sharp Clinical Services .  
 
5.9 Discontinuations of study medication  
Patients should be discontinued from study medication in the following situations:  
5.9.1 General discontinuation criteria  
1. Patient  decision.  The patient is at any time  free to discontinue  treatment,  without prejudice 
to further treatment. 
2. Adverse Events, i.e., any clinical AE, l aboratory abnormality or intercurrent illness which,  in 
the opinion  of the  investi gator, indicates  that continued  participat ion in the  study is not in 
the best interest  of the  patient.  
3. Severe  non-compliance  to protocol  as judged  by the investi gator and/or Saint Luke's Hospital of 
Kansas City . 
4. Risk to patients as jud ged by the invest igator. 
5. Incorrectly enro lled patients. 
6. Patient  lost to follow -up. 
 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 28 of 75 
 5.9.2 Study -specific discontinuation criteria  
• Doubling of  serum  creatinine  above the baseline  value confirmed by a repeated 
measure ment within  one wee k. 
• Recurrent severe  hypoglycemic  events,  defined as ≥2  severe  events (a severe  hypoglycemic 
event is defined as symptomatic events requiring external assistance due to severe 
impairment in consciousness or behavior with a capillary or plasma gl ucose value <54 
mg/dL  or blood glucose <54 mg/dL) . This definition  should  be appli ed after  possible  
contributing  factors  (eg, excessive p hysical  activi ty, dietary  and medication factors ) have  
been excluded  or addressed by the investigator.  
• Pregnancy confirmed  by a positive  pregnancy test or otherwise  verified.  
 
5.9.3 Procedures for permanent discontinuation of a patient from study medication  
Patients permanently discontinuing study medication should be given conventional therapy, if 
applicable, and should continue routine care visits with their primary physician . 
A patient that decid es to discontinue study medication will always be asked about the reason(s) for 
their desire to discontinue study medication and the presence of AEs (if any). These data will be 
ascertained and documented by the investigator .  AEs will be followed up and the patient should 
return all study medications.  
It is essential to collect as much data as possible for all patients throughout the study and especially 
all potential endpoint events. Discontinuation from study medication is n ot the same as complete 
withdrawal from the study (withdrawal of consent), which has a direct impact on the potential 
validity of all study data, and should be avoided whe never possible.  
5.9.4 Patient agrees to undergo the Premature Treatment Discontinuation Vis it and then continue 
in-person study visits  
The patient agrees to undergo the Premature Treatment Discontinuation Visit (PTDV) and  then 
continue in -person study visits according to plan. This is the preferred option and patients who 
discontinue study medic ation will always be asked if they agree to this approach. If agreed, as 
above, the patient will undergo their PTDV at the next scheduled office visit  after the study 
medication is stopped. The patient will continue attending subsequent study visits accord ing to 
schedule (Table 1 ).  
5.9.5 Patient refuses to continue in -person study visits but agrees to undergo modified follow -up 
If the patient refuses to continue in -person study visits, but agrees to undergo modified follow up, 
the in -person PTDV visit should be performed as soon as possible  after the study medication is 
stopped. All subsequent visits until the end of study date will be done as modified follow -ups (eg, 
regular telephone contacts, a contact at study closure, or other means) in order to ascertain 
whether any endpoints or safety events had occurred. Such a patient has not withdrawn his/her 
consent or withdrawn from the study.  
5.9.6 Patient refuses any form of follow -up 
If the patient refuses any form of follow -up, he/she officially withdraws from the study and 
withdraws consent. This decision must  be documented . At the end of the study, vital status on all 
such patients will be collected from publicly available sources, in accordance with local regulations.  
5.9.7 Restart of study medication  
Whenever possible, and at every study visit, restart of randomized study medication should be 
encouraged, even if a  PTDV was previously completed.  
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 29 of 75 
 5.9.8 Study Closure Visit  
All randomized patients should return for their study closure visit  (visit 8) as soon as possible, but no 
later than 1 week after the previously scheduled visit 7.  
If a patient is unable to attend the study closure visit  in person, telephone contact should be made 
to ascertain endpoint and AE information. At the study closure visit , physicians  caring for the patient 
will decide which medication the patient should receive as part of his/her ongoing clinical care.  
5.10 Withdrawal from study  
Patients are at any time free to withdraw from the study (i .e., discontinue study medication 
permanently and wit hdraw from visit assessments), without prejudice to further treatment 
(withdrawal of consent). Withdrawal of consent from the study must be ascertained and 
documented by the investigator . Such patients will always be asked about the reason(s) and the 
prese nce of any AEs. The reason for permanent discontinuation of treatment with the study 
medication and the date of the last intake of the study medication must be documented .  
5.10.1  Patients permanently discontinuing from study medication should be given conventional 
therapy, if applicable, and should always be asked to continue to attend protocol visits  
If the patient denies any additional protocol follow -up and officially withdraws consent from the 
study one of the alternatives a) to c) should be follow ed: 
• At the time of discontinuation of treatment and withdrawal of consent from continued 
assessment the patient should, if possible, undergo the PTDV. The patient should return all 
study medication  
• If the patient does not agree to this option (which must b e documented), a modified PTDV 
(eg, a telephone contact) should be arranged. The approach taken should be documented. 
The patient should return all study medication  
• If the patient does not agree to a) or b) this must be documented in the patient’s medical 
record. The patient should return all study medication.  
To ensure validity of study data, it is very important to collect as much data as possible 
throughout the study and especially vital status (dead or alive) at the SCV. The investigator or 
delegate wil l therefore attempt to collect information on all patients’ vital status from publicly 
available sources at the SCV, in accordance with local regulations, even if informed consent has 
been withdrawn completely.  
5.11 Study committees  
5.11.1  Executive Committee  (EC) 
The EC will be responsible for the overall design, including the development of the protocol and any 
protocol amendments, supervision, interpretation and reporting (presentations at international 
congresses and publications in peer reviewed journals) of the s tudy. The E C will make 
recommendations to Saint Luke’s Hospital of Kansas City  with regard to early stopping or 
modifications of the study based on the information received from the IDSMC. The E C will be 
comprised of the overall study PI  (EC Chair)  and des ignated academic leaders with expertise in the 
fields of heart failure  and cardiometabolic disease . The precise responsibilities and  procedures 
applicable for the EC will be detailed in a separate EC charter.  
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 30 of 75 
 5.11.2  Steering Committee  
A steering committee will be  formed and composed of PIs from each participating site . A publication 
plan will be developed with input from this committee.  
 
5.11.3  Clinical Endpoint Adjudication Committee (CEC)  
An independent CEC will be appointed and will adjudicate all heart failure hospitalizations , urgent 
heart failure visits and major cardiovascular events  (cardiovascular death, myocardial infarction, 
stroke) . The committee members will not have access to individual treatment codes for any patient 
or clinical efficacy  and safety event. The precise responsibilities and procedures applicable for the 
CEC will be detailed in a separate CEC charter.  
 
5.11.4  Independent Data and Safety Monitoring Committee ( IDSMC)  
An independent D SMC will be appointed . 
The IDSMC will be responsible for safeguarding the interests of the patients in the study by assessing 
the safety of the intervention during the study, and for reviewing the overall conduct of the clinical 
study. The IDSMC will have access to the individual treat ment  codes and will be able to merge these 
with the collected study data while the study is ongoing.  
The E C and Saint Luke’s Hospital of Kansas City  will not be made aware of the treatment codes until 
after clean file and database lock are declared. Simila rly, all summary output reviewed at each 
IDSMC meeting will be held in confidence by the IDSMC members until the end of the study when 
clean file and database lock are declared.  
The IDSMC charter will be prepared to detail precise roles and responsibilitie s and procedures  to 
ensure maintenance of the blinding and integrity of the study in the review of accumulating data 
and interactions with the overall s tudy PI (EC Chair) .  
The IDSMC may elect to request an Interim efficacy and /or futility  analysis at its discretion in 
consultation with the overall study PI (EC Chair).  If this option is elected, the IDSM C charter will be 
amended accordingly.    
 
6 COLLECTION OF STUDY VARIABLES  
6.1 Recording of data  
The REDCap  Web Based Data Capture (WBDC) system will be used for data collection and query 
handling. The site Principal I nvestigator will ensure that data are recorded in the electronic Case 
Report Forms (eCRF) and will ensure the accuracy, completeness, and timelin ess of the data 
recorded and of the provision of answers to data queries according to the Clinical Study Agreement 
(CSA).  
Data will be entered in the eCRF using the REDCap  Web Based Data Capture (WBDC) system by 
trained personnel at the study site.  When d ata have been entered, reviewed, edited, and source 
data verification has been performed , as appropriate , by an Saint Luke’s Hospital of Kansas City  
representative, the data will be frozen to prevent further editing. The site Principal Investigator will 
be notified to sign the eCRF electronically . A copy of the eCRF data will be archived at the study site.  
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 31 of 75 
  
6.2 Data Collection at enrollment and follow -up 
 
TABLE 3  Laboratory variables  
 
Visit  S 1 2 3 4 5 6 7 8 
Week  -2 0 2d* 10d* 4 6 9 12 13 
HbA1c  X X    X  X  
Glucose  
(included in the 
renal panel)   X    X  X  
BNP  X X    X  X  
NTproBNP  X X    X  X  
Urine albumin 
creatinine Ratio  X X    X  X X 
Urine Pregnancy 
Test X X    X  X X 
CBC   X    X  X  
Renal Panel ** X X    X  X X 
Biomarkers ***  X    X  X  
       *days after randomization                 
                                  ** The renal panel includes albumin, BUN/Creatinine Ratio (calculated), calcium,  
                                       carbon dioxide, chloride, creatinine, estimated glomeru lar filtration rate  
                                       (calculated), glucose,  phosphate (as phosphorus), potassium, sodium, urea  
                                       nitrogen  
     *** uric acid, IL-6, HS -CRP, CML, sRAGE, Gal-3, sST2 and hs-cTnT  
 
 
6.2.1 Screening  Visit P rocedures  (Visit S) 
• Informed consent  
• Blood sampling for  laboratory assessments  
• Physical exam  
• Vital Signs ( seated pulse and BP  and orthostatic pulse and BP ) 
• Weight  
• Height  
• Calculate BMI  using the height from the screening visit and the weight at the current visit  
• Urine pregnancy test (only applicable for women of childbearing potential)  
• Urine albumin /creatinine ratio  
• Medical history  
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 32 of 75 
 • Concomitant medications  
• Dispense C ARDIOKEY  monitor (if participating in the arrhythmia substudy)  
• Contact Sharp IRT for screening  
• Assess e ligibility criteria  
 
 
6.2.2 Randomi zation Visit (Visit 1 )  
Patients that fulfill the eligibility criteria will undergo randomization procedures.  
• Assess e ligibility cr iteria  
• Physical exam  
• Vital Signs ( seated pulse and BP  and orthostatic pulse and BP ) 
• Weight  
• Calculate BMI  using the height from the screening visit and the weight at the current visit  
• Fasting b lood sampling for laboratory assessments  and biomarkers  
• Urine pregnancy test (only for women of childbearing potential)  
• Urine albumin /creatinine ratio  
• Dispensed study medication  
• Dispense Urine Ketone Strips  
• Concomitant medications  
• SensiVest measurement of lung fluid volume at rest  (at selected sites) . The Sensivest test will 
only be completed on patients with a BMI of 22 -36 and a height of 61 inches to 77 inches.  
• 6 minute walk test   
• KCCQ  questionnaire  
• Adverse events  
• Serious adverse events  
• Hospitalizations , ER visits , urgent outpat ient visits for heart failure  
• Contact Sharp IRT  for randomization  
• Dispense study medication  
 
6.2.3 Visit 2, 3, 4 and 6 (phone visits ) 
• Concomitant medications  
• Adverse events  
• Serious adverse events  
• Hospitalizations, ER visits, urgent outpatient visits for heart failure  
• Self-monitored weight  
• Self-monitored Blood Glucose  (for patients with established type 2 diabetes)  
• Volume depletion monitoring  
• Ketoacidosis monitoring  
• Encourage compliance with study medication  
 
6.2.4 Visit 5 and 7 (office  visit s) 
• Physical exam  
• Vital Signs ( seated pulse and BP  and orthostatic pulse and BP ) 
• Weight  
• Calculate BMI  using the height from the screening visit and the weight at the current visit  
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 33 of 75 
 • Fasting b lood sampling for laboratory assessments  and biomarkers  
• Urine pregnanc y test (only for women of childbearing potential)  
• Urine albumin /creatinine ratio  
• Concomitant medications  
• SensiVest measurement of lung fluid volume at rest  (at selected sites) . The Sensivest test will 
only be completed on patients with a BMI of 22 -36 and a height of 61 inches to 77 inches.  
• 6 minute walk test   
• KCCQ  questionnaire  
• Concomitant medications  
• Adverse events  
• Serious adverse events  
• Hospitalizations, ER visits, urgent outpatient visits for heart failure  
• Volume depletion  monitoring  
• Ketoacidosis m onitoring  
• Dispense C ARDIOKEY  monitor ( only at V isit 5 ( Week 6)) if participating in the arrhythmia 
substudy)  
• Study medication return (redispense only at Visit 5  (Week 6) ) and accountability  
• Contact Sharp IRT  at Visit 7 for treatment completion  
 
6.2.5 Visit 8 (Study Closure Visit ) 
• Physical exam  
• Vital Signs ( seated pulse and BP  and orthostatic pulse and BP ) 
• Weight  
• Calculate BMI  using the height from the screening visit and the weight at the current visit  
• Fasting b lood sampling for laboratory assessments  (only for renal panel).  
• Urine pregnancy test (only for women of childbearing potential)  
• Urine albumin /creatinine ratio  
• Concomitant medications  
• SensiVest measurement of lung fluid volume at rest  (at selected  sites) . The Sensivest test will 
only be completed on patients with a BMI of 22 -36 and a height of 61 inches to 77 inches.  
• Adverse events  
• Serious adverse events  
• Hospitalizations, ER visits, urgent outpatient visits for heart failure  
• Volume depletion  monito ring 
• Ketoacidosis monitoring  
 
6.2.6 Premature Treatment Discontinuation Visit (PTDV)  
• Performed at next on -site visit or as soon as possible  (see section 5.9)  
• Physical exam  
• Vital Signs ( seated pulse and BP  and orthostatic pulse and BP ) 
• Weight  
• Calculate BMI  using the height from the screening visit and the weight at the current visit  
• Fasting b lood sampling for laboratory assessments  
• Urine pregnancy test (only applicable for women of childbearing potential)  
• Urine albumin /creatinine ratio  
• Concomitant medication s 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 34 of 75 
 • SensiVest measurement of lung fluid volume at rest  (at selected sites) . The Sensivest test will 
only be completed on patients with a BMI of 22 -36 and a height of 61 inches to 77 inches.  
• 6 minute walk test   
• KCCQ  questionnaire  
• Concomitant medications Adver se events  
• Serious adverse events  
• Hospitalizations, ER visits, urgent outpatient visits for heart failure  
• Volume depletion  monitoring  
• Ketoacidosis monitoring  
• Study medication return  and accountability  
• Contact Sharp IRT  for treatment discontinuation  
 
6.3 Patient Monitoring During Study Visits  
6.3.1 Patient Monitoring  
• For patients with established type 2 diabetes with a screening HbA1c of ≤ 7.0% and 
receiving insulin at baseline, it is recommended to reduce total daily insulin dose  by 20%  
at randomization . For patients with established type 2 diabetes with a screening HbA1c 
of ≤ 7.0% and receiving sulfonylurea at baseline, it is recommended to reduce total daily 
sulfonylurea dose by 50%  at randomization , or discontinue sulfonylureas  in patients 
receiving the minimal dose of sulfonylurea at baseline.    
• It is recommend ed that self -monitoring of blood glucose  (SMBG)  values is performed by 
the patients with established type 2 diabetes and reviewed during the study visits . 
• Review of glucose lowering medications should be performed at all study visits . 
Investigators are strongly encouraged to not titrate glucose -lowering medications 
during the study, unless necessary for patient safety reasons.  
• It is recommended that self -monitoring of weight  is performed by the patients and 
reviewed during the study visits , with  adjustments in loop diuretic  dose , if appropriate 
for optimization of volume status .  
 
6.3.2 Physical examination  
A physical examination  should  be done  accordi ng to schedule  shown in  Study Plan  (Table 1). 
• A complete  physical  examination  should  include  general appe arance, head, eyes, ears,  
nose, thr oat, neck,  cardiovascul ar system,  lungs, abdo men, lymph  nodes, extremities, 
neurological system, skin,  and mus culoskeletal system. Collection of pulse and blood 
pressure should also be collected as described in section 6.4. The patient should  always be 
evalua ted for the  presence of edema and other signs of volume overload (jugular 
venous distention, rales, ascites, etc).  
• Evaluation of volume depletion , including orthostatic vital signs and other physical exam 
findings consistent with dehydration  
• Evaluat ion for the presence of ketoaci dosis, in patients experiencing signs or symptoms 
of keto acidosis, such as tachypnea or hyperventilation, anorexia, abdominal pain, 
nausea, vomiting, lethargy, or mental status changes ;  administer appropriate testing for 
ketoacidosis and direct patients t o the emergency department if ketoacidosis is 
confirmed.  
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 35 of 75 
 • Baseline data are collected at Visit  1 and a ny new or aggravated  findi ngs discovered  on 
subsequent  physical examinations  should  be recorded  as AE if  clinical ly relevant . 
 
6.3.3 Phone Visits  
Phone visits should be done according to the schedule shown in Study Plan (Table 1).  
Evaluate possible AE and SAEs, medication usage, self-monitoring of weight and blood glucose  
(in patients with established type 2 diabetes) . 
 
Upon review of self -monitoring of w eight and self-monitoring glucose  (in patients with 
established type 2 d iabetes)  consider adjustments in loop diuretics and glucose -lowering 
medications for optim ization of glucose control (in patients with established type 2 diabetes) 
and volume status  if considered necessary from patient safety standpoint .  
 
6.4 Vital signs  
6.4.1 Blood pressure  and pulse  
 
Blood pressure and pulse  measurement will be taken after the patient has been sitting  and 
resting  for at least 5 minut es and before blood  samples are taken. Blood pressure (BP) and pulse 
should be measured  three times with at least 1 minute between each measurement.  BP readi ngs 
should  be taken  while  the patient  is in a comfortable  seated position  with  the arm supported  at 
the level  of the heart.   All readin gs should  be recorded.  The average of the three BP readings will 
be used for study analyses.  At screening,  the seated BP will be recorded three times in both  the 
left and the right arms.  All three  measur ements  should  be made  in one arm before transf erring 
the cuff to the oth er arm. The arm with  the highest average  seated BP readings will be the one 
used for all subs equent readings. If there is a contraindication for measuring blood pressure in an 
arm, then no measurements should be taken in that arm.  
Ideally, all blood  pressure and pulse measurements should  be taken  with  the same  automated  or 
manual  blood pressure device , at the same  time  of day, and by the same  personnel  at each visit.   
Patients with persistent atrial fibrilla tion should have all of their blood pressure and pulse 
measured with a manual cuff.  
6.4.2 Orthostatic  blood  pressure   
At visits  whe re orthostatic  BP and pulse  are collected,  supine  and standing measurements  should  
be made  after the seated  BP and pulse  measu rements  have  been made, using  the same  arm that 
was used for t he seated BP measurements.  All readings should  be recor ded. Ideally, blood  
pressure should  be measured with  the same  machine, at the same  time of d ay, and by the same 
personnel  at each visit.  
6.4.3 Supine BP and pulse   
The supine  BP and pulse  must  be measured  prior to the standing  BP and pulse. After  the p atient 
rests in the supine  position  for at least 5 minut es, supine  BP and pulse will be determined from 
three replicate measu rements obtained at least 1 mi nute apart. All three read ings must be 
record ed. For s tudy analyses, the aver age of the three BP and pulse readings will  be used. 
 
 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 36 of 75 
 6.4.4 Standing  BP and pulse   
After the supine  BP and pulse  measurements are obt ained, the patient will stand for 2 to 3 
minutes.  After  this time,  the BP will be measu red with  the arm supported  at the level  of the 
heart. Standing  BP and pulse will be determined from three replicate measurements obtained at 
least  1 minute apar t. All 3 read ings must be re corded.  For stu dy analyses, the average of the 
three BP and pulse  readings will be used. 
If a new occurrence of previous ly absent orthostatic  hypotension  is demonstrated,  it should  be 
recorded as AE. The investigator may consid er reducing  concomitant anti- hypertensive  
medi cation to alleviate  signs and symptoms  of orthostatic  hypotension.  
6.5 Six Minute Walk Test  (6MWT)  
The 6MWT is a practical simple test that requires a 100 -ft hallway but no exercise equipment or 
advanced training for technicians. Walking is an activity performed daily by all but the most severely 
impaired patients. This test measures the distance that a patient can quickly walk on a flat, hard 
surface in a period of 6 minutes  (the 6MWD). It evaluates the global and integrated responses of all 
the systems involved during exercise, including the pulmonary and cardiovascular systems, systemic 
circulation, peripheral circulation, blood, neuromuscular units, and muscle metabolism. It does not 
provide specific information on the function of each of the different organs and systems involved in 
exercise or the mechanism of exercise limitation, as is possible with maximal cardiopulmonary 
exercise testing. The self -paced 6MWT assesses th e submaximal level of functional capacity. Most 
patients do not achieve maximal exercise capacity during the 6MWT; instead, they choose their own 
intensity of exercise and are allowed to stop and rest during the test. However, because most 
activities of da ily living are performed at submaximal levels of exertion, the 6MWD may better 
reflect the functional exercise level for daily physical activities.12 
 
6.6  SensiVest Measurement of Lung  Fluid Volume  
SensiVest  utilizes remote dielectric sensing ReDS™ technology, to estimate lung fluid volumes.  The 
technology has been adapted from the military (which  used it to see inside buildings and to find 
survivors among rubble ).  Sensible Medical has adapted the same principles and created a vest that 
when worn sends low -power electromagnetic energy through the lungs, which decipher air content 
from fluid. At selected  DEFINE -HF study sites , patients ’ lung  fluid volume will be measured at rest 
(prior to 6 minute walk test) during randomization (0 weeks), 6, 12 and 13 weeks.   These results will 
be upload ed to a secure web portal and all data entry will be handled in a de -identified  and blinded  
fashion by the National Coordinating Center . The local site study staff will be blinded to the 
SensiVest results at all times. A subset of sites may offer NYHA class III patients the option to use 
SensiVest at home and readings may  be taken by the se patient s twice a day for the 13  weeks, once 
in the morning (when a patient wake s up) and once at night (when a patient  lies down to sleep).  
 
6.7 Collection of Kansas  City Cardiomyopathy Questionnaire (KCCQ)  
The KCCQ (see appendix B) is a disease -specific health status instrument compose d of 23 items that 
quantify the domains of physical limitation, symptoms, self -efficacy, social limitation, and quality of 
life limitation from heart failure. The overall summary score and all domains have been 
independently demonstrated to be valid, relia ble, and responsive to clinical change. Scores range 
from 0 to 100. For t he KCCQ overall summary score, a small but clinically meaningful change is 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 37 of 75 
 considered to be ≥ 5 points.13 The patients will fill in PRO ( KCCQ ) paper form under the supervision 
of the site staff.  
 
6.8    Laboratory  assessment s 
 
Blood and urine samples  for dete rmination  of clinical  chemist ry, hematolo gy, urinalysis and 
biomarker testing will be taken at the times indicated in the Study Plan (see Table 1).  Any additional 
laboratory safety samples taken at the investigator ’s discretion will be analy zed locally.  
It is recommended that patients do not have their baseline diuretics changed based upon  naturietic 
peptide levels, and that the patient’s primary cardiologist be blinded to the BNP and NTproBNP data 
collected throughout the trial. There have been varying r esults with trials of NTproBNP guided 
clinical management of heart failure.  Two randomized clinical trials have shown no clear benefit.23-24  
Given the uncertainty of benefit, neither serial collection nor treatment based upon NTproBNP 
levels are currentl y endorsed by ACC/AHA guidelines.25  For these reasons, it is recommended  that 
hear t failure medication changes not be made based on naturietic peptide levels.  If a patient is 
clinically symptomatic or endorses signs or symptoms of volume overload, clinical judgment should 
be used and diuretic adjustments made as warranted.   
7 BIOLOGICAL SAMPLING PROCEDURES  
7.1 Volume of b lood  
The total volume of blood that will be drawn from each patient for this study is listed in Table  4 
below. The collection of additional samples is performed locally at the discretion of the investigator 
and recorded in the eCRF as appropriate, thus req uiring additional sample volumes.  
Table 4   Volume of blood to be drawn from each patient  
Assessment  Sample volume 
(mL)  Number of 
Samples  Total Volume (mL)  
HbA1c  4 mL whole blood  4 16 mL  
Glucose  2 mL whole blood  3 6 mL  
BNP  2 mL whole blood  4 8 mL  
NTproBNP  2 mL whole blood  4 8 mL  
CBC  4 mL whole blood  3 12 mL  
Renal Panel /Uric 
Acid  
 4 mL whole blood  5 20 mL  
Biomarkers  (IL-6, 
HS-CRP, CML, 
sRAGE, Gal-3,  
ST-2 and hs-cTnT)  40 mL whole 
blood  3 120 mL  
Total    190 mL 
 
7.2 Handling, storage and destruction of biological samples  
 Blood and urine samples will be processed  by local  staff for shipment to the central laboratory 
(Quest Diagnostics).  All samples  should  be taken by adeq uately train ed study person nel and 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 38 of 75 
 handled  in accor dance with  instructions  in the central laboratory manual. Up to  date reference 
ranges will be provid ed during the  study and laboratory results  will be comp ared to the laboratory 
standard  normal ranges and flagged  if they are outsi de the normal  range. The Investi gator should  
make an assessment  of any clinical ly significant abno rmalities  in the laborato ry reports. The 
labo ratory reports  should be  signed, dated  and retained at the study site as s ource  data for 
laboratory variables.  
The clinical  chemist ry, hematolo gy, and urinalysis samples w ill be disposed after analyses.  The 
residual biomarker sample s will be stored as described in appendix C.   
 
8 SAFETY  
8.1 Definition of adverse events  (AE)  
An AE is the development of an undesirable medical condition or the det erioration of a pre -existing 
medical condition following or during exposure to a pharmaceutical product, whether or not 
considered causally related to the product. An undesirable medical condition can be symptoms (eg, 
nausea, chest pa in), signs (e .g., tach ycardia, enlarged liver) or the abnormal results of an 
investigation (e .g., laboratory findings, electrocardiogram). In clinical studies, an AE can include an 
undesirable medical condition occurring at any time, including run -in or washout periods, even if  no 
study treatment has been administered.   The term AE is used to include both serious and non -
serious AEs.  
8.2 Definitions of serious adverse event  (SAE)  
An SAE  is an AE occurring during any study phase (i .e., run -in, treatment, follow -up), that fulfil ls one 
or more of the following criteria:  
• Results in death  
• Is immediately life -threatening  
• Requires in -patient hospitalization or prolongation of existing hospitalization  
• Results in persistent or significant disability or incapacity  
• Is a congenital abnormalit y or birth defect  
• Is an important medical event that may jeopardize the patient or may require medical 
intervention to prevent one of the outcomes listed above.  
Any event of cancer, drug dependency/abuse, laboratory abnormalities fulfilling the Hy’s law 
definition or overdose (defined as the accidental or intentional ingestion of any dose of the 
investigational product that is considered both excessive and medically important) should be 
reported as an SAE using the most relevant SAE criteria, as judged by t he Investigator.  
8.2.1 Classification of Death  
Deaths will be sub -classified by CV and non -CV primary cause. CV death includes sudden cardiac 
death, death due to acute MI, death due to heart failure, death due to a cerebrovascular event, 
death due to other CV ca uses (e .g., pulmonary embolism, aortic disease, CV intervention), and 
deaths for which there was no clearly documented non -CV cause (presumed CV death).  
Additionally, deaths will be sub -classified by coronary heart diseases death (CHD death) and non -
CHD de ath. CHD death includes Sudden Cardiac Death, Death due to Acute MI, and the subset of 
Death due to other CV Causes that are secondary to a coronary revascularization procedure.  
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 39 of 75 
 8.2.2 Universal classification of Myocardial Infarction (MI)  
The Third Universal MI definition14 will be used as study specific MI criteria.  
8.2.3 Definition of Stroke  
Stroke is defined as an acute episode of neurologic dysfunction attributed to a central nervous 
system vascular cause. Stroke should be documented by imaging (eg, CT scan or magnetic resonance 
imaging [MRI] scan). Evidence obtained from autopsy can also confirm the diagnosis. Stroke will be 
sub c lassified, when possible, as either:  
8.2.4 Primary ischemic stroke  
Primary ischemic  stroke is defined as an acute episode of focal brain, spinal, or retinal  
dysfunction caused by an infarction of central nervous system tissue and documented by 
imaging. A primary  ischemic stroke may also undergo hemorrhagic transformation (i .e., no 
evidence of hemorrhage  on an initial imaging study, but appearance on a subsequent scan).  
8.2.5 Primary hemorrhagic stroke  
Primary h emorrhagic stroke is defined as an acute episode of focal o r global brain, spinal, or 
retinal dysfunction caused by non -traumatic intraparenchymal, intr aventricular, or subarachnoid 
hemorrhage as documented by neuroimaging or autopsy. Microh emorrhages (<10 mm) evident 
only on MRI are not considered to be a hemorrh agic stroke. Subdural and epidural bleeding wi ll 
be considered intracranial h emorrhage, but not strokes.  
8.2.6 Unclassified stroke  
Stroke with unknown etiology will be classified as unclassified stroke if the type of stroke could 
not be determined by imaging or other means.  
8.2.7 Hospitalizations for heart failure  
In the event that a patient is hospitalized for heart failure over the course of the study,  source 
documents will be obtained to adjudicate events . See appendix A for detailed information.  
8.2.8 Urgent outpatient visit s for heart failure  
In the event that a patient requires one or more urgent outpatient visits for heart failure  over 
the course of the study, source documents will be obtained to adjudicate events. See appendix 
A for detailed information  
8.2.9 Acute Kidney Injury  
Acute kidney injury is defined as a doubling of creatinine, consistent with the  modified  RIFLE 
criteria for stage 2 acute kidney injury . 
8.2.10   Ketoacidosis  (DKA)  
Be aware that post  marketing cases show a  possible  association between sodium -glucose 
cotransporter -2 (SGLT2) inhibitor use and the development of a high anion gap metabolic 
acidosis accompanied by elevation in urine or serum ketones , frequently in the setting of only 
mildly elevated glucose levels (euglycemic DKA) . Investigators are s trongly encouraged to 
instruct p atients and caregivers about the signs and symptoms of keto acidosis, such as 
tachypnea or hyperventilation, anorexia, abdominal pain, nausea, vomiting, lethargy, or mental 
status changes ; evaluate for the presence of ketoacidosis in patients experiencing such signs or 
symptoms  – using provided urine ketone testing kits ; discontinue study medication and advice 
patients to go to the nearest emergency department  if keto acidosis is confirmed; a nd take 
appropriate measures to correct the keto acidosis and to monitor glucose levels.  Investigators 
are also strongly encouraged to avoid concomitant risk factors potentially predisposing to DKA, 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 40 of 75 
 including carbohydrate -restricted diets and marked reducti ons in insulin dose  (for patients with 
established type 2 diabetes)  during the study  among patients receiving insulin at baseline 
(above and beyond reductions in insulin dose specified in the study protocol). Advise patients to 
alert you and seek medical attention immediately if they experience symptoms consistent with 
DKA such as:  nausea, vomiting, abdominal pain, confusion, change in breathing pattern and 
unusual fatigue or sleepiness.  
8.2.11  Volume Depletion  
Dapagliflozin has a  modest  diuretic  effect.  The risk of volume  depletion  is enhan ced when two 
diuretics  are used in com bination  and in patients  that otherw ise are at risk for vo lume depletion.  
Ther efore, caution should  be exercised  when administeri ng to patients  at risk for volume  
depletion  due to co-existing  conditions  or concomitant  medication s, such as loop diuretics.  These  
patients  should  be carefully mon itored  for volume  status, electro lytes, and renal  function, and 
encouraged to self -monitor weight during the study .  
8.3 Recording of adverse events  
8.3.1 Collection of Adverse  Events  
 AEs and SAEs  (including hospitalizations for heart failure) will be recorded from  Screening 
thro ughout  the treatment period  and includi ng the follow -up period  (Visit  8). 
All AEs/SAEs are to be recorded by the site.   SAEs, DAEs and AEs of Special Interest will be 
captured in the e -CRF.  Non -serious AEs will not be captured in the e -CRF.   
SAEs are defined in section 8.2.  
A drug adverse event (DAE) is an adverse event which leads to premature and permanent 
discontinuation of study medication.   
AEs of Special Interest will include DKA, volume depletion (defined as hypotension, syncope, 
orthostatic hypotension or dehydration) and severe hypoglycemic events.  
Information about a ll urgent outpatient heart failure visits will also be recorded by the site and 
captured in the e -CRF.  
8.3.2 Follow-up of unreso lved Adverse  Events  
Any AEs that  are unreso lved at the patient’s  last visit in the study are followed up by the 
investi gator for as long as medical ly indicated. Saint Luke’s Hospital  retains the right to request 
addition al information for any patient  with  ongoing AE(s)/SAE(s) at  the end of the  study, if 
judged necessa ry. The requ irement  to follow -up is not int ended to delay database lock or 
production of the clinical study report. Both  these activiti es should  proceed  as plann ed with  
ongoing AEs if  necessa ry. 
Any follow -up of ongoing SAEs after database  lock will be repor ted to Saint Luke’s Hospital , who 
will no tify the appropriate regulatory authorities of Saint Luke’s Hospital  and study drug 
manufacturer.  
 
 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 41 of 75 
 8.3.3 Variables   
The following  variables will be collected for each AE; 
• AE (verbatim) 
• Date  when t he AE start ed and stopped  
• Maximum  intensity 
• Whether  the AE is  serio us or not  
• Investigator  causality rating against  the Invest igational  Product  (yes or n o) 
• Action  taken  with  regard  to investi gational  product  
• Outcome  
 
In addition,  the following  variables  will be collected for SAEs:  
• Date AE m et criteria for serious AE 
• Date  Invest igator became aware of serious AE  
• AE is  serious due  to 
• Date  of hospitalization  
• Date  of disc harge 
• Probable  cause of death 
• Date  of death 
• Autop sy performed  
• Causality assessment in relation to Study procedure(s) 
• Description  of AE  
 
Maximum  intensity will be graded according to the following  rating scale: 
1. mild  (awareness of sign or symptom,  but easily tolerated) 
2. mod erate (discomfort sufficient to cause interference with  normal activiti es) 
3. severe (incapacitating, with inability to perform normal activiti es) 
 
It is important  to distin guish between  serious  and severe  AEs. Severi ty is a measure  of intensi ty. 
An AE of sev ere intensi ty need not necessarily be conside red serious. For example,  nausea  that 
persists  for several  hours may be considered  severe nausea,  but not a SAE. On the  other  hand,  a 
stroke  that results  in only a limit ed degree of disability may be conside red a mild  stroke but 
would be a  SAE. 
8.3.4 Causali ty collection  
The Investigator will assess causal relationship  betw een Investigational Product and each 
Adverse E vent, and answer ‘yes’ or ‘no’  to the question  ‘Do you consi der that there  is a 
reasonab le possibili ty that the event  may have been caused  by the invest igational  product ?’ 
For SAEs causal relationship  will also be assessed  for other  med ication and study proced ures. 
Note  that for SAEs  that could  be assoc iated  with any study procedu re the causal relationship  is 
implied as ‘yes’. 
8.3.5 Adverse Events based on signs and sy mptoms  
All AEs spontaneous ly reported  by the patient  or reported  in response  to the open  question from  
the study personne l: ‘Have  you had any health problems  since  the previous  visit/you were last 
asked?’, or revealed by observation will be collected.  When co llecting AEs, the recording of 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 42 of 75 
 diagnoses  is prefe rred (when poss ible) to recording of a list of signs and symptoms. However, if  a 
diagnosis is known and  there  are other  signs or symptoms that  are not general ly part of the 
diagnosis, the diagnosis  and each sign or symptom  will be recorded separately. 
8.3.6 Adverse Events based on exa minations  and tes ts  
The results  from protocol mandated laboratory test and vital signs will be summarized in the 
clinical  study report.  Deterioration  as com pared to baseline  in protocol -mandated  laborat ory 
values and vital signs will only be reported as AEs if they  are clinically significant, fulfill any of the  
SAE criter ia or are the reason  for disco ntinuation of treatment with  the investigational product,  
or require  the patient  to receive  specific  corrective  therapy. 
If deterioration  in a laboratory value/vital sign is associated with  clinical signs and symptoms,  the 
sign/symptom will be reported as an AE and the associated laboratory result/vital  sign will be 
considered  as additional  information.  Wherever  possible  the reporti ng inv estigator uses the 
clinical, rather  than the laboratory term (e.g., anemia versus low h emoglobin  value).  In the 
absen ce of clinical  signs or symptoms,  clinical ly relevant deteriorations  in non-mandated  
measu rements  will be reported  as AE( s). 
Any new or aggravated  clinical ly relevant  abno rmal medical  findi ng at a physical examination as 
compared with  the baseline assessment will be report ed as an AE. 
8.3.7 Hypoglyce mic events   
Information about all hypoglycemic events should be collected.  Only severe  hypoglycemic 
episodes  should be captured in the eCRF .  A severe  hypoglycemic event is defined as a 
symptomatic event requiring external assistance due to severe impairment in consc iousness or 
behavior  with a capillary or plasma gl ucose value <54 mg/dL.  
8.4 Reporting of serious adverse events  
All SAEs have to be reported to Saint Luke’s Hospital , whether or not considered causally related to 
the investigational product.  The site investigator is responsible for informing the ir local  IRB as per 
local requirements . 
Investigators and other cent er personnel must inform appropriate Saint Luke’s Hospital  
representatives via the web based data capture (WBDC) system of any SAE that occurs in the course 
of the study within 1 day (i .e., immediately but no later than the end of the next business day) of 
when he or she becomes aware of it. Follow -up information on SAEs must also be reported by the 
Investigator within the same time frame.  
An aut omated email alert will be sent to the designated Saint Luke’s Hospital  representative, when 
the page with SAE information is saved in WBDC system by the Investigators or other site personnel. 
If the WBDC system is not available, then the Investigator or o ther study site personnel reports by 
fax an SAE to the appropriate Saint Luke’s Hospital  representative. A paper back - up SAE report is 
used for this purpose. The same reporting time frames still apply. The investigator is responsible for 
completing the eC RF as soon as the system becomes available again.  
The Saint Luke’s Hospital  representative will work with the Investigator to compile all the necessary 
information and ensure that all the necessary information is provided to Saint Luke’s Hospital  within 
one calendar day of initial receipt for fatal and life threatening events and within five calendar days 
of initial receipt for all other SAEs.  
 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 43 of 75 
 8.4.1 Reporting of serious adverse events  to FDA and AstraZeneca   
 
The Sponsor (Saint Luke’s Hospital of Kansas City)  will inform the FDA, via a MedWatch/AdEERs 
form, of any serious or unexpected adverse events that occur in accordance with the reporting 
obligations of 21 CFR 312.32, and will concurrently forward all such reports to AstraZeneca .  A copy 
of the MedWa tch/AdEERs report must be faxed to AstraZeneca  at the time the event is reported to 
the FDA.  It is the responsibility of the investigator to compile all necessary information and ensure 
that the FDA receives a report according to the FDA reporting require ment timelines and to ensure 
that these reports are also submitted to AstraZeneca  at the same time.  
When reporting to AstraZeneca,  a cover page  should accompany the MedWatch/AdEERs  form 
indicating the following:  
Externally Sponsored Research  (ESR)  
The inv estigator IND number assigned by the FDA  
The investigator’s name and address  
The trial name/title and AstraZeneca ESR reference number  
Investigative site must also indicate, either in the SAE report or the cover page, the causality  of 
events in relation to  all study medications  and if the SAE is related to disease progression , as 
determined by the principal investigator.  
Send SAE report and accompanying cover page by way of fax to AstraZeneca’s  designated fax line: 
+1 302 886 4114  
Serious adverse events  that do not require expedited reporting to the FDA need to be reported to 
AstraZeneca  preferably using the MedDRA coding language for serious adverse events.   
In the case of blinded trials, AstraZeneca  may  request that the Sponsor either provide a copy of th e 
randomization code/ code break information or unblind those SAEs which require expedited 
reporting.  
All SAEs will be reported to AstraZeneca , whether or not considered causally related to the 
investigational product.  All SAEs will be documented.   
 
9 ETHI CAL AND REGULATORY REQUIREMENTS  
9.1 Ethical conduct of the study  
The study will be performed in accordance with ethical principles that have their origin in the 
Declaration of Helsinki and are consistent with ICH/Good Clinical Practice (GCP), applicable 
regula tory requirements and the Saint Luke’s Hospital of Kansas City  policy on Bioethics.  
9.2 Subject data protection  
The Informed Consent Form will incorporate (or, in some cases, be accompanied by a separate 
document incorporating) wording that complies with relev ant data protection and privacy 
legislation.  
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 44 of 75 
 9.3 Ethics and regulatory review  
An Ethics Committee/Institutional Review Board (IRB) should approve the final study protocol, 
including the final version of the Informed Consent Form and any other written informati on and/or 
materials to be provided to the patient. The investigator/Head of the study site will ensure the 
distribution of these documents to the applicable Ethics Committee/IRB, and to the study site staff.  
The opinion of the Ethics Committee should be re ceived in writing. The investigator should submit a 
notification of direction/determination as well as a copy of the IRB written approval to Saint Luke’s 
Hospital of Kansas City  before enrolment of any patient into the study.  
The Ethics Committee/IRB shoul d approve all advertising used to recruit patients for the study.  
Saint Luke’s Hospital of Kansas City  should approve any modifications to the Informed Consent Form 
that are needed to meet local requirements.  
If required by local regulations, the protocol should be re -approved by the Ethics Committee 
annually.  
Saint Luke’s Hospital of Kansas City  will provide Regulatory Authorities  (as applicable) , Ethics 
Committees/IRB and Principal Investigators with safety updates/reports according to local 
requirements, including SUSARs (Suspected Unexpected Serious Adverse Reactions), where 
relevant.  
Each Pri ncipal Investigator is responsible for providing the ir Ethics Committees/IRB with reports of 
any serious and unexpected adverse drug reactions that occur with the study medication  during the 
study, according to their local Ethics Committee/IRB regulations .  
9.4 Informed consent  
The Principal Investigator or delegate at each cent er will: 
• Ensure each patient is given full and adequate oral and written information about the 
nature, purpose, possible risk and benefit of the study  
• Ensure each patient is notified tha t they are free to discontinue from the study at any time  
• Ensure that each patient is given the opportunity to ask questions and allowed time to 
consider the information provided  
• Ensure each patient provides signed and dated informed consent before conduct ing any 
study specific procedure  
• Ensure the original, signed Informed Consent Form(s) is/are stored in the   
Investigator’s Study File  
• Ensure a copy of the signed Informed Consent Form is given to the patient  
• Ensure that any incentives for patients who part icipate in the study as well as any provisions 
for patients harmed as a consequence of study participation are described in the informed 
consent form that is approved by an Ethics Committee.  
9.5 Changes to the protocol and informed consent form  
Study procedure s will not be changed withou t the mutual agreement of the E C and Saint Luke’s 
Hospital of Kansas City . 
If there are any substantial changes to the study protocol, then these changes will be documented in 
a study protocol amendment and where required in a n ew version of the study protocol (Revised 
Clinical Study Protocol).  
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 45 of 75 
 Saint Luke’s Hospital of Kansas City  will distribute any subsequent amendments and new versions of 
the protocol to each Principal Investigator(s). If a protocol amendm ent requires a change  to a site’s 
Informed Consent Form, Saint Luke’s Hospital of Kansas City  and the site’s IRB are to approve the 
revised Informed Consent Form before the revised form is used.  
Any administrative change (s) and protocol amendment(s)  will be prepared and approv ed by the 
study sponsor ( Saint Luke’s Hospital ) and subsequently communicated to  the E C. 
9.6 Audits and inspections  
Authorized  representatives of Saint Luke’s Hospital of Kansas City , a regulatory authority, or an 
Ethics Committee may perform audits or inspect ions at the cent er, including source data 
verification. The purpose of an audit or inspection is to systematically and independently examine all 
study - related activities and documents, to determine whether these activities were conducted, and 
data were re corded, analyzed , and accurately reported according to the protocol, GCP, guidelines of 
the International Conference on Harmonization  (ICH), and any applicable regulatory requirements. 
The investigator will contact Saint Luke’s Hospital of Kansas City  immediately if contacted by a 
regulatory agency about an inspection at the cent er. 
9.7 Posting of information on clinicaltrials.gov  
Study information from this protocol will be posted on clinicaltrials.gov before  enrollment of 
patient s begins.  
 
10 STUDY MANAGEME NT BY SAINT LUKE’S HOSPITAL OF KANSAS CITY  
10.1 Pre-study activities  
Before the first patient is entered into the study, it is necessary for a representative of  Saint Luke’s 
Hospital of Kansas City  to evaluate  the investigational study site to:  
• Determine the adequacy of the facilities  
• Determine availability of appropriate patients for the study  
• Discuss with the investigator(s) (and other personnel involved with the study) their 
responsibilities with regard to p rotocol adherence, and the responsibilities of Saint Luke’s 
Hospital of Kansas City  or its representatives. This will be documented in a Clinical Study 
Agreement between Saint Luke’s Hospital of Kansas City  and the investigator.  
10.2 Training of study site pers onnel  
Before the first patie nt is entered into the study, a  Saint Luke’s Hospital of Kansas City  
representative will review and discuss the requirements of the Clinical Study Protocol and related 
documents with the investigational staff and also train them  in any study specific procedures and 
the WBDC system(s) utilized.  
The Principal Investigator will ensure that appropriate training relevant to the study is given to all of 
these staff, and that any new information relevant to the performance of this study  is forwarded to 
the staff involved.  
The Principal Investigator will maintain a record of all individuals involved in the study  (medical, 
nursing and other staff).  
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 46 of 75 
 10.3 Monitoring of the study  
During the study, a  Saint Luke’s Hospital of Kansas City  representat ive will conduct regular 
monitoring visits with the study site .  The  monitoring visits may be conducted by phone, e -mail or by 
in-person visits to the study site.  The monitoring visits  will: 
• Provide information and support to the investigator(s)  
• Confirm th at facilities remain acceptable  
• Confirm that the investigational team is adhering to the protocol, that data are being accurately 
and timely recorded in the eCRF and that study drug accountability checks are being performed  
• Perform source data verification  (a comparison of the data in the eCRF with the patient’s 
medical records at the hospital or practice, and other records relevant to the study) including 
verification of informed consent of participating patients.  
 
The Saint Luke’s Hospital of Kansas City  representative will be available between visits if the 
investigator(s) or other study site personnel need information and advice about the study conduct.  
10.4 Source data  
The Clinical Study Agreement (CSA) will specify the location of source data.  Access to so urce 
documents and source data is essential to inspection and review of clinical studies by the Food and 
Drug Administration (FDA).  
10.5 Study agreements  
The Principal Investigator at each cent er should comply with all the terms, conditions, and 
obligations of the CSA, or equivalent, for this study. In the event of any inconsistency between this 
Clinical Study Protocol and the CSA, the terms of Clinical Study Protocol shall prevail with respect to  
the conduct of the study and the treatment of patients and in all other respects, not relating to 
study conduct or treatment of patients, the terms of the CSA shall prevail.  
Agreements between Saint Luke’s Hospital of Kansas City  and the Principal Investi gator should be in 
place before any study -related procedures can take place, or patients are enrolled.  
10.6 Archiving of study documents  
The Investigator follows the principles outlined in the CSA.  
10.7 Study timetable and end of study  
The study is expected to start  in March 2016  and t o end in May 2017 . Planned  treatment du ration in 
the study is 13 weeks.  Saint Luke’s Hospital of Kansas City  will notify investigators when recruitment 
is complete.  The end of the entire study is defined as ‘the last visit of the last p atient undergoing the 
study’.  
The study may be terminated at individual centers  if the study procedures are not being performed 
according to GCP, or if recruitment is slow. Saint Luke’s Hospital of Kansas City  may also terminate 
the entire study prematurel y if concerns for safety arise within this study or in any other study with 
dapagliflozin . 
 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 47 of 75 
 11 DATA MANAGEMENT BY SAINT LUKE’S HOSPITAL OF KANSAS CITY  
Data management will be performed by Saint Luke’s Hospital of Kansas City  Data Management 
Cente r staff. Data will be entered in the WBDC system at the study site. Trained site staff will be  
responsible for entering data on the observations, tests and assessments specified in the  protocol 
into the WBDC system . Data entered in th e WBDC system will be immediately saved to a central 
database and changes tracked to provide an  audit trail. The data will then be source data verified, 
reviewed/queried and updated as needed. The Principal Investigator is responsible for electronically 
signing the eCRF. Data queries will be raised for inconsistent, improbable  or missing data. All entries 
to the study database will be available in an audit trail. The data will be frozen and then locked to 
prevent further editing. When all data have been c oded, validated, signed, and locked, a clean file 
will be declared. Any treatment revealing data may thereafter be added and the final database will 
be locked. A copy of the eCRF will be archived at the study site when the study has been locked.  
 
12 STATISTIC AL METHODS AND SAMPLE SIZE DETERMINATION  
12.1 Description of analysis sets  
12.1.1  Efficacy  analysis set  
Intention to treat (ITT) is defined as a ll patients who have been randomized to study treatment 
and completed at least one follow -up where the KCCQ and NTproBNP are collected. The ITT data 
set will be used for the primary and secondary efficacy endpoints and exploratory endpoints.  
12.1.2  Safety analysis set  
All patients who received at least 1 dose of randomized dapagliflozin  or placebo, and for whom 
post -dose data are avai lable, will be included in the safety analysis set. Throughout the safety 
results sections, erroneously treated patients (eg, those randomized to dapagliflozin  but actually 
given placebo) will be accounted for in the actual treatment group. If a patient re ceived study 
drug from the wrong kit for only a part of the treatment duration and then switched to another, 
the associated actual treatment group for that patient will be the treatment group the patient 
had the longest exposure to.  
12.2 Methods of statistical analyses  
All analyses will be on the ITT  unless otherwise specified. Baseline demographic and clinical data will 
be described between treatment and placebo study arms as mean ± standard deviation for 
continuous variables  and compared using Student’s T -test. Whereas discrete variables will be 
represented as a number and (%) and compared using the χ2 or Fisher’s exact test, as applicable .  
The time course of continuous variables will be presented using standard descriptive summary 
statistics calculated at eac h scheduled measuring time point and the last individual measuring time 
point. Moreover, standard descriptive summary statistics will be calculated for the  change (absolute 
or percent) from baseline to each scheduled measuring time point after baseline and  the last 
individual measuring time point.  
 
Due to the large number of study sites  and the expected low number of patients per site it will not 
be appropriate to explore site effects.  
 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 48 of 75 
 Statistical significance will be defined using two -sided tests with α=0.05 , unless otherwise specified . 
All statistical analyses will be performed by the Saint Luke’s Mid America Heart Institute  Department 
of Biostatistics  using SAS version 9.4  (SAS Institute, Cary, North Carolina).  
12.2.1  Primary variable  
There are two  co-primary efficacy endpoint s: 
1. Difference in mean NTproBNP between the treatment and placebo study arms at 6 and 12 
weeks.  
2. Proportion of patients that achieve a meaningful change from baseline in quality of life ( ≥ 5pts  
increase in KCCQ overall summary score)  or NT proBNP ( ≥ 20% decrease ) over 12 week 
treatment period between dapagliflozin 10 mg and placebo.  
The first co -primary endpoint of this study is to compare dapagliflozin versus placebo on mean NTproBNP 
at 6 and 12 weeks. A generalized linear mixed model with a compound symmetry covariance structure to 
estimate  the average effect over 6 and 12 weeks cont rolling for baseline NTproBNP . Gamma distribution 
and log link function will be used because of the skewness nature of NTproBNP. Center is included as a 
random factor to account for clustering of patients within centers.  
The second co -primary endpoint, proportion of patients with a  ≥ 5 point KCCQ overall summary score  
increase or a ≥ 20% decrease in NT proBNP  at 6 or 12 weeks will be analyzed using Mantel -Haenszel test 
controlling for center.  
Both co -primary endpoints will be analyzed in the entire patie nt cohort, and then within the subgroups 
of patients with and without diabetes (as pre -specified subgroup analyses).  
 
 
Statistical significance will be determined using an ordered te sting procedure ; the alpha w ill be 0.05 
for hypothesis 1. If hypothesis  1 is rejected then hypothesis 2 will be tested  at α=0.05 level. 
However , if hypothesis 1 is not rejected hypothesis 2 will not be tested.  
12.2.2  Secondary variables  
The following secondary efficacy variables have been identified:  
3. Proportion of patients with a ≥ 5pt s increase in KCCQ  over 12 weeks  
4. Proportion of patients with a ≥ 20% decrease in NTproBNP  over 12 weeks  
5. Proportion of patients with a ≥ 5pts increase in KCCQ and a ≥ 20% decrease in NTproBNP  over 
12 weeks  
6. Change in KCCQ score over 12 weeks.  
7. Change in 6 min ute walk score over 12 weeks.  
8. Difference in mean  BNP at 6 and  12 weeks.  
9. Change in HbA1c over 12 weeks.   (evaluated separately in patients with and without type 2 
diabetes)  
10. Change in weight over 12 weeks  
11. Change in systolic blood pressure over 12 weeks  
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 49 of 75 
 For secondary analyses proportional comparisons will be analyzed using the same testing method 
as the primary analyses. For continuous variable comparisons an analysis of covariance (ANCOVA) 
model including terms for treatment group and baseline covariate.  The ANCOVA model will be 
used to derive the treatment difference with 95% confidence interval and corresponding two -
sided p -value. Additionally, the mean change within each treatment group will be calculated with 
corresponding 95% confidence intervals.  
Secondary endpoints will be analyzed in the entire patient cohort, and then within the subgroups of 
patients with and without diabetes (as pre -specified subgroup analyses).  
 
12.2.3  Exploratory variables  
The following exploratory variables have been identified:  
1. Effects on average weekly loop diuretic dose (furosemide equivalent).  
2. Effects on the rate of hospitalizations for heart failure.  
3. Effects on rate of urgent outpatient heart failure visits . 
4. Effects on the rate of hospitalizations for heart failu re and urgent outpatient heart failure visits . 
5. Change in NYHA Class over 12 weeks.  
6. Change in NTproBNP and KCCQ at 6 weeks from baseline and 12 weeks from baseline . 
7. Effect on lung fluid volumes measured by remote dielectric sensing  ReDS™ ( SensiVest ) over the 
treatment period . 
8. Change in mean lung fluid volumes measure d by remote dielectr ic sensing  ReDS™ (SensiVest ) 
between week 12 and week 13 . 
Exploratory data will be summarized descriptively and presented by treatment group.  Exploratory 
endpoints will be analyzed in the entire patient cohort, and then within the subgroups of patients with 
and without diabetes (as pre -specified subgroup analyses).  
 
12.2.4  Safety variables  
The safety evaluations will include the analyses of all AEs  of special interest  and SAEs, however the 
following safety variables have been identified a priori : 
1. All cause death  
2. Cardiovascular death  
3. Non -fatal myocardial infarction (MI)  
4. Stroke  
5. Acute kidney injury (defined as doubling of serum creatinine based on the RIFLE criteria)  
6. Volume Depletion  
7. Severe hypoglycemic events  
8. Ketoacidosis  
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 50 of 75 
 Safety data will be summarized descriptively and presented by treatment group.  
12.2.5  Analysis for safety  
Safety analyses will be done periodically during the study and reported to the IDSMC. A formal 
IDSMC charter will be developed . 
12.3 Determination of sample size  
For t he first co -primary endpoint a sample size of 110 for each group will achieve 80% power with α=0.05 
to detect a reduction in NTproBNP be tween the two groups of at least 302  pg/mL from baseline to 12 
weeks. The assumptions for this calculation were derived from the BATTLESCARRED  trial where the 
estimated standard deviation for NTproBNP was 1250 pg/mL. We expect the standard deviation in the 
DEFINE -HF Trial to be somewhat lower (961 pg/ml) given lower NTproBNP threshold. Of note, 302pg/mL 
reduction in NTproBNP is equivalent to 31.5% of the standard deviation in NTproBNP (base d on the 
above assumption).  
The second co -primary endpoint is a combined endpoint of a ≥ 5 point KCCQ overall summary score 
increase  or a ≥ 20% decrease in NT proBNP. The sample size was determined using two independent 
groups where the anticipated contro l group percent change is 30%.  A sample size of 110 for each group 
will achieve 80% power with α=0.05 to detect a difference in proportional change between the two 
groups of 1 8% from baseline to 12 weeks for the second co -primary endpoint.  
There is an ant icipated loss to follow -up of approximately 13 % so the final s ample size per group will 
be 125 . 
13 IMPORTANT MEDICAL PROCEDURES TO BE FOLLOWED BY THE 
INVESTIGATOR  
13.1 Medical emergencies and Saint Luke’s Hospital  Contacts  
The Principal Investigator is responsible  for ensuring that procedures and expertise are available to 
handle medical emergencies during the study. A medical emergency usually constitutes an SAE and 
is to be reported as such . 
In the case of a medical emergency the investigator may contact the Stud y Team Physician at  Saint 
Luke’s Hospital of Kansas City . 
 
 
Name  Role in the study  Address & telephone number  
Mikhail Kosiborod , MD  Lead Study Team Physician 
responsible for the protocol  Saint Luke’s Hospital of Kansas City  
4401 Wornall R oad 
Kansas City, MO 64111  
Email: Phone: 816 -932-3445  
Cell:  203-988-3134  
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 51 of 75 
 Sheryl Windsor, MBA, MT(ASCP)  Study Manager  Saint Luke’s Hospital of Kansas City  
4401 Wornall R oad 
Kansas City, MO 64111  
Email:  
Phone: 816 -932-9858  
Cell: 816 -695-7561  
 
13.2 Overdose  
Overdose is defined as the accidental or intentional ingestion of any dose of investigational product 
that is considered both excessive and medically important. Dapagliflozin has been well tolerated at 
doses of up to 500 mg/day in single dose testing in he althy volunteers and up to 100 mg/day in 
repeat dose testing for 14 days in healthy volunteers and patients with type 2 diabetes .  If an 
overdose is suspected, monitoring of vital functions  as well as treatment , as appropriate , should be 
performed.  If an o verdose occurrence meets the criteria for a Serious Adverse Event , then it must be 
reported as Serious Adverse Event . 
13.3 Pregnancy  
Any pregnancy during the course of this study should be recorded .  Pregnancy itself is not regarded 
as an Adverse Event unless there is a suspicion that the investigational product under study may 
have interfered with the effectiveness of a contraceptive medication.  
 If any pregnancy occurs in the course of the study, the patient should be discontinued, the 
investigational product should be stopped and then investigators or other site personnel must 
inform appropriate Saint Luke’s Hospital  representatives immediately but no later than the end of 
the next business day of when he or she becomes aware of it.  
 
14 BIOMARKER SUBSTUDY  
A biomarker substudy will be conducted.  Specimens will be collected for e xploratory biomarker testing 
from all patients at the Randomization, Week 6 and Week 12 visits t o assess the impact of dapagliflozin  
versus placebo on known markers of myoca rdial fibrosis/necrosis, inflammation, and oxidative stress .  
Detailed collection, processing, storage and shipment instructions are provided in the central laboratory 
manual.   Information regarding the biomarker substudy is included in appendix C.  
 
15 FUTURE RESEARCH  
The residual sample from the biomarker substudy will be stored indefinitely to allow for possible future 
research.   Information regarding the storage and possible use of banked biospecimens is included in 
appendix C.  
 
16 ARRYTHMIA SUBSTUDY  
An arrhythmia substudy will be conducted.  Patient participation will be optional. At the screening visit , 
those likely to be enrolled will be given the option to participate in the arrhythmia substudy. If they elect 
to enroll they will wear a holter monit or for 14 days to establish a baseline.   The 14 -day holter will be 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 52 of 75 
 repeated at the 6 -week visit to compare change in arrhythmia burden.   Information regarding the 
arrhythmia substudy is included in appendix D.  
 
17  SensiVest Lung Fluid Volume M easurements  
 
SensiVest utilizes remote dielectric sensing ReDS™ technology, to estimate lung fluid volumes.  The 
technology has been adapted from the military who used it to see inside buildings and to find survivors 
among rubble.  Sensible Medical has ad apted the same principles and created a vest that when worn 
sends low -power electromagnetic energy through the lungs, which decipher air content from fluid19. 
Two sensors are attached to the body: one anteriorly on the chest and the other on the back of th e 
patient. Each sensor both transmits and receives the energy either reflected from or transferred through 
the pulmonary tissue. The signal received reflects the dielectric properties of the section of the lung 
between the sensors.  Water has a very high d ielectric coefficient while air in contrast has the lowest 
dielectric coefficient. These physical properties make pulmonary tissue ideal to sensitively quantify the 
ratio of fluid to air (or in the case of heart failure estimate volume status and pulmonary  edema).2  The 
device has received both FDA 510k clearance and European CE mar kings for non -invasive lung fluid 
monitoring. The waves emitted are low frequency, which do not interfere with any other implantable 
devices17. The accuracy of ReDS was first established using CT as a gold standard and correlating changes 
in ReDS values among porcine models of heart failure undergoing both fluid challenge and then diuresis.  
As a part of the study , patients at selected sites will have  blinded  lung/fluid volume measure ments  at 
rest during the randomization  (week 0) , 6, 12 and 13 week  visits .  Site personnel will remain blinded to 
the Sensivest measurement results; de -identified and blinded Sensivest measurements will be accessible 
to th e National Coordinating Center staff.  (See appendix E for further details).  
 
18 REFERENCES  
1. Go, A. S.  et al.  Heart disease and stroke statistics --2014 update: a report from the American 
Heart Association. Circulation  129 , e28 -e292, doi:01.cir.0000441139.02102.80 [pii]  
10.1161/01.cir.0000441139.02102.80 (2014).  
2 McMurray, J. J.  et al.  Angiotensin -neprilysin inhibition versus enalapril in heart failure. N 
Engl J Med  371 , 993 -1004, doi:10.1056/NEJMoa1409077 (2014).  
3 Parving, H. -H. et al.  Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes. New 
England Journal of Medicine  367 , 2204 -2213, doi:10.1056/NEJMoa1208799 (2012).  
4 Bertoni, A. G.  et al.  Heart failure prevalence, incidence, and mortality in the elderly with 
diabetes. Diabetes Care  27, 699 -703 (2004).  
5 Erdmann, E.  et al.  Pioglitazone use and heart failure in patients with type 2 diabetes and 
preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes 
Care  30, 2773 -2778, doi:dc07 -0717 [pii]  
10.2337/dc07 -0717 (2007).  
6 Komajda, M.  et al.  Heart  failure events with rosiglitazone in type 2 diabetes: data from the 
RECORD clinical trial. Eur Heart J  31, 824 -831, doi:ehp604 [pii]  
10.1093/eurheartj/ehp604 (2010).  
7 Ryden, L., Thrainsdottir, I. & Swedberg, K. Adjudication of serious heart failure in pa tients 
from PROactive. Lancet  369 , 189 -190, doi:S0140 -6736(07)60106 -8 [pii]  
10.1016/S0140 -6736(07)60106 -8 (2007).  
8 Scirica, B. M.  et al.  Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes 
mellitus. N Engl J Med  369 , 1317 -1326, doi:10 .1056/NEJMoa1307684 (2013).  
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 53 of 75 
 9 White, W. B.  et al.  Alogliptin after acute coronary syndrome in patients with type 2 diabetes. 
N Engl J Med  369 , 1327 -1335, doi:10.1056/NEJMoa1305889 (2013).  
10 Gerstein, H. C.  et al.  Long -term effects of intensive glucose low ering on cardiovascular 
outcomes. N Engl J Med  364 , 818 -828, doi:10.1056/NEJMoa1006524 (2011).  
11 Inzucchi, S. E.  et al.  SGLT -2 inhibitors and cardiovascular risk: proposed pathways and 
review of ongoing outcome trials. Diab Vasc Dis Res  12, 90-100, 
doi:10 .1177/1479164114559852 (2015).  
12 Neal, B.  et al.  Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. New 
England Journal of Medicine  0, null, doi:10.1056/NEJMoa1611925.  
13 Zinman, B.  et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. 
N Engl J Med , doi:10.1056/NEJMoa1504720 (2015).  
14 Fitchett, D.  et al.  <div xmlns=" http://www.w3.org/1999/xhtml  failure outcomes with 
empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the 
EMPA -REG OUTCOME<sup>®</sup> trial</div>. European Heart Journal , 
doi:10.1093/eurheartj/ehv728 (2016).  
15 Neal, B.  et al.  Rationale, design, and baseline characteristi cs of the Canagliflozin 
Cardiovascular Assessment Study (CANVAS) —a randomized placebo -controlled trial. Am 
Heart J  166 , doi:10.1016/j.ahj.2013.05.007 (2013).  
16 Kosiborod, M.  et al.  Lower Risk of Heart Failure and Death in Patients Initiated on SGLT -2 
Inhi bitors Versus Other Glucose -Lowering Drugs: The CVD -REAL Study. Circulation , 
CIRCULATIONAHA. 117.029190 (2017).  
17 Scheerer, M.  et al.  Gesamtereignisraten für die Hospitalisierung bei Herzinsuffizienz (HHI) 
bei Neueinstellung auf SGLT -2-Hemmer im Vergleich  zu anderen Antidiabetika –Daten aus 
dem klinischen Alltag aus Deutschland, Schweden und Norwegen mit mehr als 45.000 Typ 2 
Diabetes Patienten (CVD -Real). Diabetologie und Stoffwechsel  12, LB12* (2017).  
18 Inzucchi, S. E.  et al.  SGLT -2 inhibitors and cardio vascular risk: proposed pathways and 
review of ongoing outcome trials. Diab Vasc Dis Res  12, doi:10.1177/1479164114559852 
(2015).  
19 EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection 
Fraction (EMPEROR -Reduced). ClinicalTrials.gov 2017; 
https://clinicaltrials.gov/ct2/show/[STUDY_ID_REMOVED]?term=03057977&rank=1  
20 EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved 
Ejection Fraction (EMPEROR -Preserved). ClinicalTrials.gov 2017; 
https://clinicaltrials.gov/ct2/show/[STUDY_ID_REMOVED]?term=03057951&rank=1  
21 Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or 
Cardiovascular Death in Patients With Chronic Heart Failure (Dapa -HF). ClinicalTrials.gov 
2017; https://clinicaltrials.gov/ct2/show/[STUDY_ID_REMOVED]?term=03036124&rank=1  
22 Kosiborod, M., Gause -Nilsson, I., Sonesson, C. & Johnsson, E. in DIABETOLOGIA.   S368 -S368 
(SPRINGER 233 SPRING ST, NEW YORK, NY 10013 USA).  
23 Lainchbury JG, Troughton RW, Strangman KM, Frampton CM, Pilbrow A, Yandle TG, Hamid 
AK, Nicholls MG and Richards AM. N -terminal pro -B-type natriuretic peptide -guided 
treatment for chronic heart failure: results from the BATTLESCARRED (NT -proBNP -
Assisted Tr eatment To Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll 
Cardiol . 2009;55:53 -60. 
24 Pfisterer M, Buser P, Rickli H, Gutmann M, Erne P, Rickenbacher P, Vuillomenet A, Jeker U, 
Dubach P, Beer H, Yoon SI, Suter T, Osterhues HH, Schieber MM, H ilti P, Schindler R, 
Brunner -La Rocca HP and Investigators T -C. BNP -guided vs symptom -guided heart failure 
therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With 
Congestive Heart Failure (TIME -CHF) randomized trial. JAMA . 2009;301:383 -92 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 54 of 75 
 25 Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr., Drazner MH, Fonarow GC, Geraci SA, 
Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, 
McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW,  Tang WH, Tsai EJ, 
Wilkoff BL, American College of Cardiology F and American Heart Association Task Force on 
Practice G. 2013 ACCF/AHA guideline for the management of heart failure: a report of the 
American College of Cardiology Foundation/American Heart A ssociation Task Force on 
Practice Guidelines. J Am Coll Cardiol . 2013;62:e147 -239 
 
 
 
 
  
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 55 of 75 
 19 APPENDIX A: HEART FAILURE HOSPITALIZATION /URGENT OUTPATIENT VISIT  
A Heart Failure Event includes hospitalization for heart failure and may include urgent outpatient visits. 
Heart failure  hospitalizations should remain delineated from urgent visits.  
 
A Heart Failure Hospitalization is defined as an event that meets ALL of the following criteri a: 
 
• The patient is admitted to the hospital with a primary diagnosis of heart failure  
• The patient’s length -of-stay in hospital extends for at least 24 hours (or a change in calendar 
date if the hospital admission and discharge times are unavailable)  
• The patient exhibits documented new or worsening symptoms due to heart failure on 
presentation, including at least ONE  of the following:  
 
o Dyspnea (dyspnea with exertion, dyspnea at rest, orthopnea, paroxysmal nocturnal 
dyspnea)  
o Decreased exercise tolerance   
o Fatigue  
o Other symptoms of worsened end -organ perfusion or volume overload  
 
• The patient has objective evidence of new or worsening heart failure , consisting of at least TWO  
physical examination findings OR one physical examination finding and at least ONE  laboratory 
criterion), including:  
 
o Physical examination findings considered to be due to heart failure, including new or 
worsened:  
▪ Peripheral edema  
▪ Increasing abdominal distention or ascites (in the absence of primary hepatic 
disease)  
▪ Pulmonary rales/crac kles/crepitations  
▪ Increased jugular venous pressure and/or hepatojugular reflux  
▪ S3 gallop  
▪ Clinically significant or rapid weight gain thought to be related to fluid  retention  
 
o Laboratory evidence of new or worsening heart failure , if obtained within 24 hou rs of 
presentation, including:  
▪ Increased B -type natriuretic peptide (BNP)/ N -terminal pro -BNP (NT - proBNP) 
concentrations consistent with decompensation of heart failure (such as BNP > 
500 pg/mL or NT -proBNP > 2,000 pg/mL). In patients with chronically ele vated 
natriuretic peptides, a significant increase should be noted above baseline.  
▪ Radiological evidence of pulmonary congestion  
▪ Non -invasive or invasive diagnostic evidence of clinically significant elevated 
left- or right -sided ventricular filling pressu re or low cardiac output. For 
example, echocardiographic criteria could include: E/e’ > 15  or D -dominant 
pulmonary venous inflow pattern, plethoric inferior vena cava with minimal 
collapse on inspiration  
OR 
▪ Invasive diagnostic evidence with right heart cat heterization showing a 
pulmonary capillary wedge pressure (pulmonary artery occlusion  pressure) • 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 56 of 75 
 ≥18 mmHg, central venous pressure ≥ 12 mmHg, or a cardiac  index < 2.2  
L/min/m2 
 
• The patient receives initiation or intensification of treatment specifically for heart failure , 
including at least ONE  of the following:  
 
o Augmentation in oral diuretic therapy  
o Intravenous diuretic, inotrope, or vasodilator therap y 
o Mechanical or surgical in tervention, including:  
▪ Mechanical circulatory support (e.g., intra -aortic balloon pump, ventricular 
assist device)  
▪ Mechanical fluid removal (e.g., ultrafiltration, hemofiltration, dialysis) Using 
available information, Heart Failure will be categorized bas ed on the following:  
• Left ventricular ejection fraction (LVEF)  
• Type  
• Etiology  
 
• An Urgent Heart Failure Visit is defined as an event that meets all of the following:  
 
▪ The patient has an urgent, unscheduled office/practice or emergency 
department visit for a primary diagnosis of heart failure , but not meeting the 
criteria for a heart failure  hospitalization.  
▪ All signs and symptoms for heart failure  hospitalization (i.e., 3) symptoms; 4) 
physical examination findings/laboratory evidence of new or worsening heart 
failure, as indicated above) must be met  
▪ The patient receives initiation or intensification of treatment specifically for 
heart failure , as detailed in the above section.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 57 of 75 
 20 APPENDIX B: KANSAS CITY CARDIOMYOPATHY QUESTIONNAIRE (KCCQ)  
 
Kansas City Cardiomyopathy Questionnaire (KCCQ)  
 
The following questions refer to your heart failure  and how it may affect your life.  Please read and 
complete the following questions.  There are no right or wrong answers.  Please mark the answer that 
best applies to you.  
1.   Heart failure  affects different people in different ways.  Some feel shortness of breath while 
others feel fatigue.  Please indicate how much you are limited by heart failure  (shortness of 
breath or fatigue) in your ability to do the following activities over the past 2 weeks .  
Activity  Extremely 
Limited  Quite a bit 
Limited  Moderatel y 
Limited  Slightly 
Limited  Not at all 
Limited  Limited for other 
reasons or did not 
do the activity  
Dressing yourself        
Showering/Bathing        
Walking 1 block on 
level ground        
Doing yardwork, 
housework or 
carrying groceries        
Climbing a flight of 
stairs without 
stopping        
Hurrying or jogging 
(as if to catch a bus)        
 
2.  Compared with 2 weeks ago , have your symptoms of heart failure (shortness of breath, 
fatigue, or ankle swelling) changed?   
 
 My symptoms of heart failure  have become…  
Much worse  Slightly 
worse  Not changed  Slightly better  Much better  I’ve had no symptoms 
over the last 2 weeks  
      
 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 58 of 75 
 3.  Over the past 2 weeks , how many times did you have swelling  in your feet, ankles or legs 
when you woke up in the morning?  
 
Every morning  3 or more times 
a week, but not 
every day  1-2 times a week  Less than once a 
week  Never over the 
past 2 weeks  
     
 
 
4.  Over the past 2 weeks , how much has swelling  in your feet, ankles or legs bothered you?  
 It has been ...  
Extremely 
bothersome  Quite a bit 
bothersome  Moderately 
bothersome  Slightly  
bothersome  Not at all 
bothersome  I’ve had no 
swelling  
      
 
 
5.  Over the past 2 weeks , on average, how many times has fatigue  limited your ability to do 
what you  want?  
All of the 
time  Several times 
per day  At least once 
a day  3 or more times 
per week but not 
every day  1-2 times 
per week  Less than once a 
week  Never over 
the past 2 
weeks  
       
 
 
1.  Over the past 2 weeks,  how much has your  fatigue bothered you?  
 It has been ...  
Extremely 
bothersome  Quite a bit 
bothersome  Moderately 
bothersome  Slightly  
bothersome  Not at all 
bothersome  I’ve had 
no fatigue  
      
 
7. Over the past 2 weeks , on average, how many times has shortness of breath  limited your 
ability to do what you wanted?  
All of the 
time  Several times 
per day  At least once 
a day  3 or more times 
per week but not 
every day  1-2 times 
per week  Less than once a 
week  Never over 
the past 2 
weeks  
       
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 59 of 75 
  
8.  Over the past 2 weeks,   how much has your shortness of breath  bothered you?  
 It has been ...  
Extremely 
bothersome  Quite a bit 
bothersome  Moderately 
bothersome  Slightly  
bothersome  Not at all 
bothersome  I’ve had no 
shortness of breath  
      
 
9.  Over the past 2 weeks,  on average, how many times have you been forced to sleep sitting up 
in a chair or with at least 3 pillows to prop you up  because  of shortness of breath ? 
 
Every night  3 or more times a 
week, but not every day  1-2 times a 
week  Less than once 
a week  Never ov er the 
past 2 weeks  
     
 
10.  Heart failure  symptoms can worsen for a number of reasons.  How sure are you that you know what 
to do, or whom to call, if your heart failure  gets worse?  
 
Not at all  sure  Not very  sure  Somewhat  sure  Mostly  sure  Completely  sure  
     
 
 
11.  How well do you understand what things you are able to do to keep your heart failure  symptoms 
from getting worse? (for example, weighing yourself, eating a low salt diet etc.)  
 
Do not understand  
at all  Do not understand 
very well  Somewhat 
understand  Mostly 
understand  Completely 
understand  
 
12.  Over  the past 2 weeks , how much has your heart failure  limited your enjoyment of life?  
 
It has extremely 
limited my 
enjoyment of life  It has limited  my 
enjoyment of life 
quite a bit  It has moderately  
limited my 
enjoyment of life  It has slightly  
limited my 
enjoyment of life  It has not limited  
my enjoyment of 
life at all  
     
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 60 of 75 
  
13.  If you had to spend the rest of your life with your heart failure  the way it is right now , how 
would you feel about this?  
Not at all 
satisfied  Mostly 
dissatisfied  Somewhat 
satisfied  Mostly 
satisfied  Completely 
satisfied  
     
 
 
14.  Over the past 2 weeks , how often have you felt discouraged or down in the dumps because of 
your heart failure ? 
I felt that way 
all of the time  I felt that way 
most of the time  I occasionally  
felt that way  I rarely  felt that 
way I never  felt that 
way 
     
 
15.  How much does your heart failure  affect your lifestyle?  Please indicate how your heart 
failure may have limited your participation in the following activities over the past 2 weeks.  
Please place an X in one box on each line  
 
Activity   
Severely 
limited   
Limited  quite a 
bit  
Moderately 
limited   
Slightly 
limited   
Did not limit  
at all  Does not apply 
or did not do for 
other reasons  
Hobbies, 
recreational 
activities   
  
  
  
  
  
 
Working or doing 
household chores   
  
  
  
  
  
 
Visiting  family or 
friends out of your 
home     
  
  
  
 
Intimate 
relationships with 
loved ones   
  
  
  
  
  
 
Place an X in one box on each line  
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 61 of 75 
 21 APPENDIX C: BIOMARKER SUBSTUDY  
Type 2 diabetes (DM) and prediabetes exacerbate the complications of all forms of cardiovascular 
disease, and particularly heart failure.1, 2  DM can directly affect the myocardium, leading to increased 
left ventricular (LV) hy pertrophy, altered LV remodeling, and reduced systolic and diastolic function.3 In 
the presence of hypertension or ischemia/infarction, DM  worsens adverse LV remodeling and 
dysfunction, which results in worse heart failure (HF) symptoms and increased mortality.4-6   
The recently released EMPA -REG OUTCOME trial noted a 38% relative risk reduction of cardiovascular 
death  with empagliflozin, a SGLT -2 inhibitor, versus placebo in patients with diabetes and established 
CVD .7 Though the trial was predominantly of diabetic patients with coronary  artery disease, the majority 
of the benefit appeared to be due to the reduction in hospitalizations for heart failure (a 35% relative 
risk reduction ), and prevention of heart failure related and arrhythmia -related deaths.  The mechanism 
of action for such a dramatic benefit in prevention of HF and cardiovascular mortality is not well 
understood , but does not appear to be due to the glucose lowering effects of empagliflozin.  
It is therefore  likely that mechanisms  beyond glucose  lowering and diuresis  are behind the reduction in 
HF events and CV mortality with SGLT -2 inhibitors.8 We hypothesize that the majority of the benefit of 
SGLT -2 inhibitors in HF is due to a reduction in oxidative stress, (thus improving both sy stolic and 
diastolic function), improvement in endothelial function (thus decreasing vessel stiffness) and possible 
neurohormonal and anti -inflammatory effects.  Supporting this hypothesis are rat models where SGLT -2 
inhibition was shown to normalize endot helial function, reduce oxidative stress in aortic vessels, reverse 
a pro -inflammatory phenotype, and improve AGE/RAGE signaling all pathways of potential importance 
to a reduction in arterial stiffness.9  
The biomarker substudy will address the following Specific Aims:  
1. Specific Aim #1: To assess the impact of dapagliflozin vs. placebo on known markers of myocardial 
fibrosis/necrosis, inflammation, and oxidative stress in patients with chronic HF  with reduced systolic 
function  (with and without diabetes)  
 
We will m easure systemic biomarkers of oxidative stress: Uric Acid, Fibrosis: galectin -3 (Gal3 ), ST-2, 
myocyte necrosis: High sensitivity cardiac troponin T (hs -cTnT),  and inflammation: high -sensitivity C 
reactive protein  (hsCRP), interleukin -6 (Il-6). (See Appendix C Biomarker Summary Table ).  The change in 
biomarkers between 0, 6 and 12  weeks will be compared between dapaglif lozin and placebo.   
Anticipated results:  We hypothesize that multiple biomarkers reflecting dive rse biological  pathways 
would be significantly decreased in patients receiving dapaglif lozin vs. placebo.  Our overarching 
hypothesis is that patients taking dapaglif lozin for 12 weeks will have a significantly greater reduction in 
biomarkers of oxidative stress (one of the most likely underlying mechanisms of benefit of SGLT -2 
inhibitors) than those on placebo.  
2. Specific Aim #2: Examine the relationship between biomarkers of myocardial fibrosis /necrosis, 
inflammation,  and oxidative stress and clinical outcomes, including heart failure specific biomarkers 
(BNP, NTproBNP), as well as patients’ symptoms and functional status (KCCQ and 6 -minute walk test)  
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 62 of 75 
 Linear regression will be employed with heart failure specific biomarkers (BNP, NTproBNP). KCCQ and 6 
minute walk, as dependent variables  (separate models); independent variables will include biomarker s 
of oxidative stress, fibrosis /necrosis, inflammation and other potential confounders; the bio markers will 
be included in separate models and chosen based on the strongest univariable relationships between 
biomarkers and the clinical outcomes.  
Anticipated results:   We hypothesize that those patients with the greatest clinical benefit (by BNP, 
NTpro BNP, KCCQ or 6 min walk) will be those with a significant reduction in pro inflammatory, fibrotic, 
and oxidative stress biomarkers.  
3. Specific Aim #3: Preserve residual blood specimens (banked biospecimens) for long -term storage so that 
evaluations for addi tional biomarkers or genetic analyses could be performed in the future.  
 
To protect subjects’ confidentiality, the banked biospecimens and data generated from them will be 
coded with the subject’s study ID number.  Samples will be kept in a secure storage area.  Data will be 
stored on password -protected computer systems. The key between the code and the subject’s personal 
identifiers will be held at the study site; the researchers using the biospecimens and data generated 
from them will not have access to t he key nor any personally identifying information.  
 
It is very unlikely that results generated from the banked biospecimens will have any clinical, diagnostic, 
or therapeutic implications for the individual study participants.  Subjects are notified in the  informed 
consent document that their results will not be given to them, to family members or other physicians; 
nor will they be recorded in the subject’s medical record.  
 
A research proposal would be submitted to the Saint Luke’s Hospital  IRB for approva l of any future 
analysis that might be conducted on the banked biospecimens.  
 
 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 63 of 75 
  
 
 
 
 
 
  
 
 
 
Appendix C Biomarker Summary Table:   
Circulating 
biomarkers  Background, rationale, and measurement  
Inflammatory  
(IL-6, HS -CRP)  •  Several proinflammatory cytokines such as C -reactive protein (CRP), interleukine -6 
(IL-6) seem to play a role in the low -grade systemic inflammation observed in 
diabetics.  
• HS-CRP is increased in heart failure.  Higher levels are associated with feature s of 
more severe heart failure and are independently associated with mortality and 
morbidity s10 
Advanced glycation 
end-products  
(AGEs)  
(CML, sRAGE ) • AGEs (circulating carboxymethyl -lysine [CML] and soluble receptor for AGEs 
[sRAGE]) are products of nonen zymatic glycation and oxidation which are known to 
rapidly accumulate in vessel walls of diabetics.11   
• In Mouse RAGE mediates inflammatory signaling, is involved in diabetic macro and 
microvascular complicati ons, and is associated with increased muscle, cartilage, and 
vascular stiffness.12-14 Given the adverse effects of AGEs i n diabetes, AGEs may play 
a particularly important role in the pathobiology of heart failure in diabetics  
Stress/Fibrosis  
(Gal-3, soluble ST2 ) • Galectin 3 is a biomarker that is actively involved in both inflammatory and fibrotic 
pathways of cardiac remodeling. Elevated levels of galectin -3 have been found to be 
significantly associated with higher risk of death in both acute decompensated heart 
failure and chronic heart failure populations.19 
•  Soluble ST2 signals the presence and severity of adverse cardiac remodeling and 
fibrosis. Its levels are elevated in both diabetics and heart failure with reduce ejection 
fraction, and prognosti c of morbidity and mortality.18 
Oxidative Stress  
(Uric Acid ) • In Mouse models SGLT -2 have shown to decrease oxidative stress.  This is 
perhaps confirmed as many trials of SGLT -2 have demonstrated a decrease in uric 
acid.21 It is unclear whether the decrease in Uric Acid is through renal loss or truly 
by a d ecrease in oxidative stress.   
Myocardial 
Necrosis:  
(High sensitivity 
cardiac troponin T 
(hs-cTnT)  
 •  High‐sensitivity troponin assays represent an important advance with added 
sensitivity for cardiac myocyte necrosis , therefore allowing  risk stratification and 
prognostic information in stable disease states  such as chronic systolic heart failure. 
23, 24 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 64 of 75 
 References:  
1. Kannel WB and McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA . 
1979;241:2035 -8. 
2. Mak KH and Topol EJ. Emerging concepts in the management of acute myocardial infarction in 
patients with diabetes mellitus. J Am Coll Cardiol . 2000;35:563 -8. 
3. Devereux RB, Roman MJ, Paranicas M, O'Grady MJ, Lee ET, Welty TK, Fabsitz RR, Robbins D, Rho ades 
ER and Howard BV. Impact of diabetes on cardiac structure and function: the strong heart study. 
Circulation . 2000;101:2271 -6. 
4. Abbott RD, Donahue RP, Kannel WB and Wilson PW. The impact of diabetes on survival following 
myocardial infarction in men vs women. The Framingham Study. JAMA . 1988;260:3456 -60. 
5. Bella JN, Devereux RB, Roman MJ, Palmieri V, Liu JE, Paranicas M, Welty TK, Lee ET, Fabsitz RR and 
Howard BV. Separate and joint effects of systemic hypertension and diabetes mellitus on left ventr icular 
structure and function in American Indians (the Strong Heart Study). Am J Cardiol . 2001;87:1260 -5. 
6. Palmieri V, Bella JN, Arnett DK, Liu JE, Oberman A, Schuck MY, Kitzman DW, Hopkins PN, Morgan D, 
Rao DC and Devereux RB. Effect of type 2 diabetes mellitus on left ventricular geometry and systolic 
function in hypertensive subjects: Hypertension Genetic Epidemiology Network (HyperGEN) study. 
Circulation . 2001;103:102 -7. 
7. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, De vins T, Johansen OE, 
Woerle HJ, Broedl UC, Inzucchi SE and Investigators E -RO. Empagliflozin, Cardiovascular Outcomes, and 
Mortality in Type 2 Diabetes. The New England journal of medicine . 2015.  
8. Inzucchi SE, Zinman B, Wanner C, Ferrari R, Fitchett D, H antel S, Espadero RM, Woerle HJ, Broedl UC 
and Johansen OE. SGLT -2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing 
outcome trials. Diabetes & vascular disease research . 2015;12:90 -100.  
9. Oelze M, Kroller -Schon S, Welschof P, Ja nsen T, Hausding M, Mikhed Y, Stamm P, Mader M, Zinssius E, 
Agdauletova S, Gottschlich A, Steven S, Schulz E, Bottari SP, Mayoux E, Munzel T and Daiber A. The 
sodium -glucose co -transporter 2 inhibitor empagliflozin improves diabetes -induced vascular dysfun ction 
in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity. PloS one . 
2014;9:e112394.  
10. Anand IS, Latini R, Florea VG, Kuskowski MA, Rector T, Masson S, Signorini S, Mocarelli P, Hester A, 
Glazer R, Cohn JN and Val -He FTI. C -reactive protein in heart failure: prognostic value and the effect of 
valsartan. Circulation . 2005;112:1428 -34. 
11. Yan SF, Ramasamy R, Naka Y and Schmidt AM. Glycation, inflammation, and RAGE: a scaffold for the 
macrovascular complications of diabetes and beyond. Circulation research . 2003;93:1159 -69. 
12. Aronson D. Cross -linking of glycated collagen in the pathogenes is of arterial and myocardial 
stiffening of aging and diabetes. J Hypertens . 2003;21:3 -12. 
13. Ulrich P and Cerami A. Protein glycation, diabetes, and aging. Recent progress in hormone research . 
2001;56:1 -21. 
14. Yan SF, Ramasamy R and Schmidt AM. Mechanis ms of disease: advanced glycation end -products and 
their receptor in inflammation and diabetes complications. Nature clinical practice Endocrinology & 
metabolism . 2008;4:285 -93. 
15. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morga n JP, Sellke FW, Stillman 
IE, Epstein FH, Sukhatme VP and Karumanchi SA. Excess placental soluble fms -like tyrosine kinase 1 
(sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin 
Invest . 2003;111:649 -58. 
16. Izumiya Y, Shiojima I, Sato K, Sawyer DB, Colucci WS and Walsh K. Vascular endothelial growth factor 
blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to 
pressure overload. Hypertension . 2006;47:887 -93. 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 65 of 75 
 17. Ky  B, French B, Ruparel K, Sweitzer NK, Fang JC, Levy WC, Sawyer DB and Cappola TP. The vascular 
marker soluble fms -like tyrosine kinase 1 is associated with disease severity and adverse outcomes in 
chronic heart failure. J Am Coll Cardiol . 2011;58:386 -94. 
18. Bhardwaj A and Januzzi JL, Jr. ST2: a novel biomarker for heart failure. Expert review of molecular 
diagnostics . 2010;10:459 -64. 
19. van Kimmenade RR, Januzzi JL, Jr., Ellinor PT, Sharma UC, Bakker JA, Low AF, 19. Martinez A, Crijns 
HJ, MacRae CA, Menhe ere PP and Pinto YM. Utility of amino -terminal pro -brain natriuretic peptide, 
galectin -3, and apelin for the evaluation of patients with acute heart failure. Journal of the American 
College of Cardiology . 2006;48:1217 -24. 
20. Anand IS, Kempf T, Rector TS, Tapken H, Allhoff T, Jantzen F, Kuskowski M, Cohn JN, Drexler H and 
Wollert KC. Serial measurement of growth -differentiation factor -15 in heart failure: relation to disease 
severity and prognosis in the Valsartan Heart Failure Trial. Circulation . 2010;122: 1387 -95. 
21. Rosenstock J, Aggarwal N, Polidori D, Zhao Y, Arbit D, Usiskin K, Capuano G, Canovatchel W and 
Canagliflozin DIASG. Dose -ranging effects of canagliflozin, a sodium -glucose cotransporter 2 inhibitor, as 
add-on to metformin in subjects with type 2 diabet es. Diabetes care . 2012;35:1232 -8. 
22. Knight RK, Miall PA, Hawkins LA, Dacombe J, Edwards CR and Hamer J. Relation of plasma 
aldosterone concentration to diuretic treatment in patients with severe heart disease. British heart 
journal . 1979;42:316 -25. 
23. Apple FS, Collinson PO and Biomarkers ITFoCAoC. Analytical characteristics of high -sensitivity cardiac 
troponin assays. Clinical chemistry . 2012;58:54 -61. 
24. Twerenbold R, Jaffe A, Reichlin T, Reiter M and Mueller C. High -sensitive troponin T measurements : 
what do we gain and what are the challenges? European heart journal . 2012;33:579 -86. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 66 of 75 
 22 APPENDIX D: ARR HYTHMIA SUBSTUDY  
 
Heart Failure (HF) is associated with significant morbidity and mortality, with overall 60 -day mortality 
among clinical trial patients hospitalized for CHF estimated as high as 10 percent.1 It has been 
demonstrated that patients with NYHA class I –III tend to die sudd enly whereas the death is usually due 
to refractory failure in those with Class IV symptomatology.2 Estimates from the  Framingham study 
show sudden cardiac death which occurs in 30 –50% of patients with heart failure.3   
It has been shown that beta -blockade and spironolactone reduce such arrhythmias thereby reducing 
sudden death and total mortality.4, 5  Additionally , both have been shown to decrease premature 
ventricular complexes (PVCs) and non -sustained ventricular tachycardia (NSVT), which have both been 
shown t o correlate with sudden cardiac death in HF patients.6 
The recently released EMPA -REG OUTCOME trial noted a 38% relative risk reduction of cardiovascular 
death with empagliflozin, a SGLT -2 inhibitor, versus placebo in patients with diabetes and established 
CVD.7 Though the trial was predominantly of diabe tic patients with coronary artery disease (an overall 
low risk population for arrhythmia and sudden cardiac death compared to HF patients), empagliflozin 
demonstrated a 31% relative risk reduction of sudden cardiac death compared to placebo.  
Atrial arrhyt hmias are also associated with significant morbidity and mortality amo ngst patients with 
HF.8  Numerous animal models and some small series of humans demonstrated a potential benefit of 
thiazolidinedione  (TZD) in reducing atrial fibrillation amongst diabetic  patients .9, 10  It was theorized that 
this was through a pleiotropic effect perhaps secondary to anti-inflammatory and antioxidant effects of 
TZDs.11 While the mechanism of benefit of SGLT -2 on cardiovascular outcomes is unknown  taking into 
consideration the aforeme ntioned improvement in cardiac death, sudden cardiac death, death due to 
worsening HF, and HF hospitalization it cou ld be speculated that this is also likely secondary to 
pleiotropic effects . It is therefore that we hypothesize  dapaglif lozin might exert be neficial effects on 
atrial remodeling reducing AF burden among patients  with HF  (with an d without type 2 diabetes) .  
Arrhythmia sub study design:  
At screening visit ( -2 weeks) those likely to be enrolled will be given  the option to participate in the 
arrhy thmia sub study. If they elect to enroll they will wear  a CARDIOKEY  holter monitor for 14 days to 
establish a baseline.   The 14 -day holter will be repeated  at the 6 -week visit to compare change in 
arrhythmia  burden.  
When a patient has completed wearing the monitor for 14 days they will send the monitor in a pre paid 
package to Cardionet for processing.  The coordinating center (Saint Luke ’s Mid America Heart  Institute ) 
will have a portal with data from all study locations underneath it for data processing and interpretation. 
Each site will be assigned the necessary number of CARDIOKEY  devices , and replacement units ship 
automatically when a unit is enrolled w ith a patient.   These are shipped second -day air via UPS, so we 
can set it up so there are enough inventories at each site.  
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 67 of 75 
 Outcomes of sustained VT episodes , non-sustained VT ( NSVT ) episodes , VF episodes, atrial fibrillation, 
PVCs and PACs  will be compar ed between dapaglif lozin and placebo  (see representative  table ). 
Power Calculation  for decrease in PVCs/hour.  
Ramires et al reported a baseline PVC/hour burden of 65 +15, this amongst a cohort of NYHA class III 
patients.  After 16 weeks of spironolactone the PVC/hour burden decreased to 17 +9.  Given that the 
patient population of DEFINE -HF population will be less “sick” (NYHA class II and III), we are predicting a 
baseline PVC burden of 50+15 per hour.  Assuming a 14% reduction in PVC per ho ur after 6 weeks of 
dapaglif lozin; 98 patients would be required in each cohort to achieve 90% power (see Appendix D Table 
1).  
Appendix D Table 1.  
Placebo (PVC/Hr)  Dapaglif lozin N for each arm  Power  
50+15 40+15 36 80%  
50+15 43+15 73 80%  
50+15 45+15 142 80%  
50+15 47+15 393 80%  
 
Ventricular arrhythmias  
 
 
 
 
 
Atrial arrhythmias  
 
 
 
 
P evaluated with Independent sample  t-test.  Outcomes  Dapaglif lozin  Placebo  P value  
VT episodes     
NSVT episodes     
VF episodes     
PVC Burden     
Outcomes  Dapaglif lozin  Placebo  P value  
A fib burden     
PAC burden     
A fib episodes     
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 68 of 75 
 NSVT: non -sustained ventricular tachycardia, VF: ventricular fibrillation, VT: ventricular tachycardia, PVC: 
premature ventricular contractions , A fib : Atrial fibrillation  
 
Representative figure adapted from ( The American Journal of Cardiology, Volume 85, Issue 10, 2000, 
1207 –1211 ) 
 
 
 
 
 
 
 
 
 
 

 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 69 of 75 
  
 

 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 70 of 75 
  
 

 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 71 of 75 
  
References:  
1.Gattis WA, O'Connor CM, Gallup DS, Hasselblad V, Gheorghiade M, Investigators I -H and Coordinators. 
Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of 
the Initiation Management Predischarge: Process f or Assessment of Carvedilol Therapy in Heart Failure 
(IMPACT -HF) trial. Journal of the American College of Cardiology . 2004;43:1534 -41. 
2. Luu M, Stevenson WG, Stevenson LW, Baron K and Walden J. Diverse mechanisms of unexpected 
cardiac arrest in advanced heart failure. Circulation . 1989;80:1675 -80. 
3. Kannel WB, Plehn JF and Cupples LA. Cardiac failure and sudden death in the Framingham S tudy. 
American heart journal . 1988;115:869 -75. 
4. Ramires FJ, Mansur A, Coelho O, Maranhao M, Gruppi CJ, Mady C and Ramires JA. Effect of 
spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or 
to ischemic c ardiomyopathy. The American journal of cardiology . 2000;85:1207 -11. 
5. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, 
Roecker EB, Schultz MK, DeMets DL and Carvedilol Prospective Randomized Cumulative Surviv al Study 
G. Effect of carvedilol on survival in severe chronic heart failure. The New England journal of medicine . 
2001;344:1651 -8. 
6. Doval HC, Nul DR, Grancelli HO, Varini SD, Soifer S, Corrado G, Dubner S, Scapin O and Perrone SV. 
Nonsustained ventricul ar tachycardia in severe heart failure. Independent marker of increased mortality 
due to sudden death. GESICA -GEMA Investigators. Circulation . 1996;94:3198 -203.  
7. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johans en OE, 
Woerle HJ, Broedl UC, Inzucchi SE and Investigators E -RO. Empagliflozin, Cardiovascular Outcomes, and 
Mortality in Type 2 Diabetes. The New England journal of medicine . 2015.  
8. Swedberg K, Olsson LG, Charlesworth A, Cleland J, Hanrath P, Komajda M,  Metra M, Torp -Pedersen C 
and Poole -Wilson P. Prognostic relevance of atrial fibrillation in patients with chronic heart failure on 
long -term treatment with beta -blockers: results from COMET. European heart journal . 2005;26:1303 -8. 
9. Korantzopoulos P, Kok koris S, Kountouris E, Protopsaltis I, Siogas K and Melidonis A. Regression of 
paroxysmal atrial fibrillation associated with thiazolidinedione therapy. International journal of 
cardiology . 2008;125:e51 -3. 
10. Anglade MW, Kluger J, White CM, Aberle J and C oleman CI. Thiazolidinedione use and post -operative 
atrial fibrillation: a US nested case -control study. Current medical research and opinion . 2007;23:2849 -
55. 
11. Liu T, Korantzopoulos P, Li G and Li J. The potential role of thiazolidinediones in atrial f ibrillation. 
International journal of cardiology . 2008;128:129 -30. 
 
 
 
 
 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 72 of 75 
  
23   Appendix E: SensiVest Remote Dielectric Sensing ReDS™ to Assess Lung 
Fluid Volumes  (at selected sites)  
SensiVest utilizes remote dielectric sensing ReDS™ technology, to estimate lung fluid volumes.  The 
technology has been adapted from the military who used it to see inside buildings and to find survivors 
among rubble.  Sensible Medical has adapted the same  principles and created a vest that when worn 
sends low -power electromagnetic energy through the lungs, which decipher air content from fluid.1   Two 
sensors are attached to the body: one anteriorly on the chest and the other on the back of the patient. 
Each sensor both transmits and receives the energy either reflected from or transferred through the 
pulmonary tissue. The signal received reflects the dielectric properties of the section of the lung between 
the sensors.  Water has a very high dielectric coefficient while air in contrast has the lowest dielectric 
coefficient. These physical properties make pulmonary tissue ideal to sensitively quanti fy the ratio of fluid 
to air (or in the case of heart failure estimate volume status and pulmonary edema).2  
The device has received both FDA 510k clearance and European CE ma rkings for non -invas ive lung fluid 
monitoring. The waves emitted are low frequenc y, which do not interfere with any other implantable 
devices.1  
The accuracy of ReDS was first established using CT as a gold standard and correlating changes in ReDS 
values among porcine models of heart failure undergoing both fluid challenge and then diu resis. At 
selected  DEFINE -HF study sites  patients lung/fluid volume will be measured at randomization (0 weeks), 
6, 12 and 13 week  visits at rest . The overarching hypothesis  is that those on dapagliflozin will have a 
significantly lower percentage of fluid  in their lungs than those on placebo.  
Additionally in an attempt to gather more data and correlate lung fluid volumes with heart failure specific 
quality of life, and biomark ers of fibrosis and remodeling some patients with NYHA class III heart failure 
at select sites may be able to  take a SensiVest home and transmit twice daily lung fluid volumes between 
randomization and week 13. Patients enrolled prior to SensiVest being av ailable at the trial site will not 
have any Sensivest measurements preformed.  A number of exploratory endpoints will be assessed with 
this data:  
Specific Aim #1:  To assess the impact of dapaglifloz in vs. placebo on  lung fluid volumes  in patients with 
Hear t Failure with reduced systolic function.  
We will measure  sedentary baseline lung fluid volume by percentage at 0, 6, 12 and 13 -week office visits 
and compare values between dapagliflozin and placebo.  
Anticipated results:  We hypothesize that there will be  a significa ntly lower percentage of lung fluid in 
patients receiving dapagliflozin vs. placebo.  Similarly we hypothesize that on cessation of dapagliflozin  or 
placebo, lung fluid concentration will increase in patients treated with dapagliflozin to a gre ater extent 
than in those treated with placebo.  
 
 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 73 of 75 
 Specific Aim # 2: Examine the relationship between lung fluid volume and clinical outcomes, including 
heart failure specific biomarkers (BNP, NTproBNP), as well as patients’ symptoms and functional status 
(KCCQ and 6 -minute walk test), heart failure hospitalization and urgent visits for heart failure.  
Anticipated results:  We hypothesize that those patients with the greatest reductions in lung fluid volume 
will be those with the greatest clinical benefit (by  BNP, NTproBNP, KCCQ or 6 min walk).  
Specific Aim #3:  Examine the relationship between lung fluid volume and novel heart failure biomarkers 
Uric Acid, myeloperoxidase level (MPO), Fibrosis: galectin -3 (Gal3) , soluble ST -2, Myocyte necrosis: High 
sensitivity cardiac troponin T (hs -cTnT),  and Inflammation: high -sensitivity C reactive protein (hsCRP), 
interleukin -6 (Il-6).  
Anticipated results:  We hypothesize that those patients with the greatest reductions in lung fluid volu me 
will be those with a significant reduction in pro inflammatory, fibrotic, and oxidative stress biomarkers.  
 
References : 
1. http://sensible -medical.com/ . 1/26/2015  
2. Rappaport D. Noninvasive Monitoring of Pulmonary Congestion Using a Remote Dielectric Sensing 
(ReDS) System: A Prospective Single -Arm Study in Patients Suffering from Heart Failure. Journal of 
cardiac failure; 18(8):S61 doi: 10.1016/j.cardfail.2012.06.207[published Online First: Ep ub Date]|.  
3. Amir O, Rappaport D, Zafrir B, et al. A novel approach to monitoring pulmonary congestion in heart 
failure: initial animal and clinical experiences using remote dielectric sensing technology. Congestive 
heart failure 2013; 19(3):149 -55 doi: 10 .1111/chf.12021[published Online First: Epub Date]|.  
4. Abraham WT, Amir O, Weinstein JM, et al. Remote Dielectric Sensing (ReDS&#x2122;) -Guided Patient 
Management of Ambulatory Heart Failure Patients Reduces Rehospitalization Rates. Journal of cardiac 
failure; 21(8):S77 doi: 10.1016/j.cardfail.2015.06.240[published Online First: Epub Date]|.  
5. Sensible Medical Innovations Lung fLuid Status Monitor Allows rEducing Readmission Rate of Heart 
Failure Patients (SMILE™). Clinicaltrialsgov 2015; 
https://clinicalt rials.gov/ct2/show/record/[STUDY_ID_REMOVED]?term=sensible&rank=1   
 
 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 74 of 75 
   
 
 
 
 
 

 
 
DEFINE -HF Protocol Final v3.0                                                                                                    Page 75 of 75 
  
 
24   APPENDIX F: PRINCIPAL INVESTIGATOR SIGNATURE  
 
SIGNATURE OF PRINCIPAL INVESTIGATOR  
 
  
Dapagliflozin EFfect on symptoms and b Iomarkers i N patiEnts with 
Heart Failure (DEFINE -HF) 
 
  
 
I agree to the terms of this study protocol. I will conduct the study according to the procedures 
specified herein, and according to the principles of Good Clinical Practice and local regulations.  
 
 
Site Number:  ____________  
  
Signature:  
   
 Signature of Principal Investigator  
 
_____________________________________  
Principal Investigator Name (print or type)  
 Date  
   
This document contains confidential information, which should not be copied, referred to, 
released or published without written approval. Investigators are cautioned that the 
information in this protocol may be subject to change and revision.  
 